Keywords
Last Name
Institution

Gareth Morgan

TitleProfessor
InstitutionUniversity of Arkansas for Medical Sciences
DepartmentCollege of Myeloma Institute
Address4104 Outpatient Circle
Mail Slot # 816
Little Rock AR 72205
Phone501-526-6990
vCardDownload vCard
    Other Positions
    TitleProfessor
    InstitutionUniversity of Arkansas for Medical Sciences
    DepartmentPathology, College of Medicine


    Collapse Overview 
    Collapse overview
    Gareth Morgan, M.D. FRCP, FRCPath, Ph.D, Professor of Medicine, is the Director of the Myeloma Institute at UAMS. Dr. Morgan came to UAMS from The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research in London where he was a Professor of Haematology and Director of the Centre for Myeloma Research.Dr. Morgan received his doctorate on the genetics of leukemia from the University of London in 1991 and his bachelor of medicine in 1981 from the Welsh National School of Medicine. Since 2003, he has served as a professor of Hematology and director of the Centre for Myeloma Research at the Royal Marsden NHS Foundation Trust and The Institute of Cancer Research in London, Europe's largest comprehensive cancer institute. Morgan is a director of Myeloma UK, the UK's respected patient organization, as well as a member of the Scientific Board of the International Myeloma Foundation and Scientific Secretary for the UK Myeloma Forum. He is also a founding director of the European Myeloma Network.PublicationsVideos from the Patient Power NetworkAdditional Videos featuring Dr. MorganTo make an appointment with Dr. Morgan, please call 1-888-MYELOMA.


    Collapse Research Funds 

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Morgan GJ, Kenny D, Duke C, Walsh KP, Qureshi SA. Initial assessment of a novel delivery system (NuDEL™ ®) for the covered Cheatham-Platinum stent. Cardiol Young. 2017 Oct; 27(8):1465-1469. PMID: 28857726.
      View in: PubMed
    2. Bhutani M, Zhang Q, Friend R, Voorhees PM, Druhan LJ, Barlogie B, Sonneveld P, Morgan GJ, Symanowski JT, Avalos BR, Copelan EA, Usmani SZ. Investigation of a gene signature to predict response to immunomodulatory derivatives for patients with multiple myeloma: an exploratory, retrospective study using microarray datasets from prospective clinical trials. Lancet Haematol. 2017 Sep; 4(9):e443-e451. PMID: 28863804.
      View in: PubMed
    3. Pawlyn C, Morgan GJ. Evolutionary biology of high-risk multiple myeloma. Nat Rev Cancer. 2017 Aug 24; 17(9):543-556. PMID: 28835722.
      View in: PubMed
    4. Johnson DC, Lenive O, Mitchell J, Jackson G, Owen R, Drayson M, Cook G, Jones JR, Pawlyn C, Davies FE, Walker BA, Wardell C, Gregory WM, Cairns D, Morgan GJ, Houlston RS, Kaiser MF. Neutral tumor evolution in myeloma is associated with poor prognosis. Blood. 2017 Aug 21. PMID: 28827410.
      View in: PubMed
    5. Kang SL, Jivanji S, Mehta C, Tometzki AJ, Derrick G, Yates R, Khambadkone S, de Giovanni J, Stumper O, Dhillon R, Bhole V, Slavik Z, Rigby M, Noonan P, Smith B, Knight B, Richens T, Wilson N, Walsh K, James A, Thomson J, Bentham J, Hayes N, Nazir S, Adwani S, Shauq A, Ramaraj R, Duke C, Taliotis D, Kudumula V, Yong SF, Morgan G, Rosenthal E, Krasemann T, Qureshi S, Crossland D, Hermuzi T, Martin RP. Outcome after transcatheter occlusion of patent ductus arteriosus in infants less than 6 kg: A national study from United Kingdom and Ireland. Catheter Cardiovasc Interv. 2017 Aug 11. PMID: 28799706.
      View in: PubMed
    6. Campbell JP, Heaney JLJ, Pandya S, Afzal Z, Kaiser M, Owen R, Child JA, Gregory W, Morgan GJ, Jackson GH, Bunce CM, Drayson MT. Active multiple myeloma suppresses and typically eliminates coexisting MGUS. Br J Cancer. 2017 Sep 05; 117(6):835-839. PMID: 28728165.
      View in: PubMed
    7. Meziane I, Huhn S, da Silva Filho MI, Weinhold N, Campo C, Nickel J, Hoffmann P, Nöthen MM, Jöckel KH, Landi S, Mitchell JS, Johnson D, Jauch A, Morgan GJ, Houlston R, Goldschmidt H, Milani P, Merlini G, Rowcieno D, Hawkins P, Hegenbarth U, Palladini G, Wechalekar A, Försti A, Schönland SO, Hemminki K. Genome-wide association study of clinical parameters in immunoglobulin light chain amyloidosis in three patient cohorts. Haematologica. 2017 Jul 04. PMID: 28679651.
      View in: PubMed
    8. Goreczny S, Qureshi SA, Rosenthal E, Krasemann T, Nassar MS, Anderson DR, Morgan GJ. Comparison of self-expandable and balloon-expanding stents for hybrid ductal stenting in hypoplastic left heart complex. Cardiol Young. 2017 Jul; 27(5):837-845. PMID: 28555538.
      View in: PubMed
    9. Heaney JLJ, Campbell JP, Griffin AE, Birtwistle J, Shemar M, Child JA, Gregory WM, Cairns DA, Morgan G, Jackson G, Drayson MT. Diagnosis and monitoring for light chain only and oligosecretory myeloma using serum free light chain tests. Br J Haematol. 2017 Jul; 178(2):220-230. PMID: 28573706.
      View in: PubMed
    10. Mohan M, Buros A, Mathur P, Gokden N, Singh M, Susanibar S, Jo Kamimoto J, Hoque S, Radhakrishnan M, Matin A, Davis C, Grazziutti M, Thanendrarajan S, van Rhee F, Zangari M, Davies F, Morgan G, Epstein J, Barlogie B, Schinke C. Clinical characteristics and prognostic factors in multiple myeloma patients with light chain deposition disease. Am J Hematol. 2017 Aug; 92(8):739-745. PMID: 28383130.
      View in: PubMed
    11. Scales M, Chubb D, Dobbins SE, Johnson DC, Li N, Sternberg MJ, Weinhold N, Stein C, Jackson G, Davies FE, Walker BA, Wardell CP, Houlston RS, Morgan GJ. Search for rare protein altering variants influencing susceptibility to multiple myeloma. Oncotarget. 2017 May 30; 8(22):36203-36210. PMID: 28404951.
      View in: PubMed
    12. Mikulasova A, Wardell CP, Murison A, Boyle EM, Jackson GH, Smetana J, Kufova Z, Pour L, Sandecka V, Almasi M, Vsianska P, Gregora E, Kuglik P, Hajek R, Davies FE, Morgan GJ, Walker BA. The spectrum of somatic mutations in monoclonal gammopathy of undetermined significance indicates a less complex genomic landscape than that in multiple myeloma. Haematologica. 2017 Sep; 102(9):1617-1625. PMID: 28550183.
      View in: PubMed
    13. Thanendrarajan S, Tian E, Qu P, Mathur P, Schinke C, van Rhee F, Zangari M, Rasche L, Weinhold N, Alapat D, Bellamy W, Ashby C, Mattox S, Epstein J, Yaccoby S, Barlogie B, Hoering A, Bauer M, Walker BA, Davies FE, Morgan GJ. The level of deletion 17p and bi-allelic inactivation of TP53 has a significant impact on clinical outcome in multiple myeloma. Haematologica. 2017 Sep; 102(9):e364-e367. PMID: 28550191.
      View in: PubMed
    14. Schinke C, Hoering A, Wang H, Carlton V, Thanandrarajan S, Deshpande S, Patel P, Molnar G, Susanibar S, Mohan M, Mathur P, Radhakrishnan M, Hoque S, Jo Kamimoto J, Grazziutti M, van Rhee F, Zangari M, Insuasti-Beltran G, Alapat D, Post G, Yaccoby S, Epstein J, Rasche L, Johnson S, Moorhead M, Willis T, Barlogie B, Walker B, Weinhold N, Davies FE, Morgan GJ. The prognostic value of the depth of response in multiple myeloma depends on the time of assessment, risk status and molecular subtype. Haematologica. 2017 Aug; 102(8):e313-e316. PMID: 28522572.
      View in: PubMed
    15. Rasche L, Angtuaco E, McDonald JE, Buros A, Stein C, Pawlyn C, Thanendrarajan S, Schinke C, Samant R, Yaccoby S, Walker BA, Epstein J, Zangari M, van Rhee F, Meissner T, Goldschmidt H, Hemminki K, Houlston R, Barlogie B, Davies FE, Morgan GJ, Weinhold N. Low expression of hexokinase-2 is associated with false-negative FDG-positron emission tomography in multiple myeloma. Blood. 2017 Jul 06; 130(1):30-34. PMID: 28432222.
      View in: PubMed
    16. Rasche L, Weinhold N, Morgan GJ, van Rhee F, Davies FE. Immunologic approaches for the treatment of multiple myeloma. Cancer Treat Rev. 2017 Apr; 55:190-199. PMID: 28431262.
      View in: PubMed
    17. Mohan M, Samant RS, Yoon D, Buros AF, Branca A, Montgomery CO, Nicholas R, Suva LJ, Morello R, Thanendrarajan S, Schinke C, Yaccoby S, van Rhee F, Davies FE, Morgan GJ, Zangari M. Extensive Remineralization of Large Pelvic Lytic Lesions Following Total Therapy Treatment in Patients With Multiple Myeloma. J Bone Miner Res. 2017 Jun; 32(6):1261-1266. PMID: 28240368.
      View in: PubMed
    18. Tumber A, Nuzzi A, Hookway ES, Hatch SB, Velupillai S, Johansson C, Kawamura A, Savitsky P, Yapp C, Szykowska A, Wu N, Bountra C, Strain-Damerell C, Burgess-Brown NA, Ruda GF, Fedorov O, Munro S, England KS, Nowak RP, Schofield CJ, La Thangue NB, Pawlyn C, Davies F, Morgan G, Athanasou N, Müller S, Oppermann U, Brennan PE. Potent and Selective KDM5 Inhibitor Stops Cellular Demethylation of H3K4me3 at Transcription Start Sites and Proliferation of MM1S Myeloma Cells. Cell Chem Biol. 2017 Mar 16; 24(3):371-380. PMID: 28262558.
      View in: PubMed
    19. Law PJ, Sud A, Mitchell JS, Henrion M, Orlando G, Lenive O, Broderick P, Speedy HE, Johnson DC, Kaiser M, Weinhold N, Cooke R, Sunter NJ, Jackson GH, Summerfield G, Harris RJ, Pettitt AR, Allsup DJ, Carmichael J, Bailey JR, Pratt G, Rahman T, Pepper C, Fegan C, von Strandmann EP, Engert A, Försti A, Chen B, Filho MI, Thomsen H, Hoffmann P, Noethen MM, Eisele L, Jöckel KH, Allan JM, Swerdlow AJ, Goldschmidt H, Catovsky D, Morgan GJ, Hemminki K, Houlston RS. Genome-wide association analysis of chronic lymphocytic leukaemia, Hodgkin lymphoma and multiple myeloma identifies pleiotropic risk loci. Sci Rep. 2017 Jan 23; 7:41071. PMID: 28112199.
      View in: PubMed
    20. Carmo Mendes I, Heard H, Peacock K, Krasemann T, Morgan GJ. Echocardiographic Versus Angiographic Assessment of Patent Arterial Duct in Percutaneous Closure: Towards X-ray Free Duct Occlusion? Pediatr Cardiol. 2017 Feb; 38(2):302-307. PMID: 28078384.
      View in: PubMed
    21. Morgan GJ, Jones JR. Integration of Genomics Into Treatment: Are We There Yet? Am Soc Clin Oncol Educ Book. 2017; 37:569-574. PMID: 28561666.
      View in: PubMed
    22. Goreczny S, Bedair R, Bilska K, Morgan G. Retrieving a large embolised atrial septal occluder - hooked… and landed. Kardiol Pol. 2017; 75(3):277. PMID: 28326525.
      View in: PubMed
    23. Goreczny S, Morgan GJ, Dryzek P, Moll JA, Moszura T. Initial experience with live three-dimensional image overlay for ductal stenting in hypoplastic left heart syndrome. EuroIntervention. 2016 Dec 20; 12(12):1527-1533. PMID: 27998845.
      View in: PubMed
    24. Bedair R, Morgan GJ, Bapat V, Kapetanakis S, Goreczny S, Simpson J, Qureshi SA. Early experience with the Occlutech PLD occluder for mitral paravalvar leak closure through a hybrid transapical approach. EuroIntervention. 2016 Dec 10; 12(11):e1420-e1427. PMID: 26690317.
      View in: PubMed
    25. Li N, Johnson DC, Weinhold N, Studd JB, Orlando G, Mirabella F, Mitchell JS, Meissner T, Kaiser M, Goldschmidt H, Hemminki K, Morgan GJ, Houlston RS. Multiple myeloma risk variant at 7p15.3 creates an IRF4-binding site and interferes with CDCA7L expression. Nat Commun. 2016 Nov 24; 7:13656. PMID: 27882933.
      View in: PubMed
    26. Jethava YS, Mitchell A, Epstein J, Zangari M, Yaccoby S, Tian E, Waheed S, Khan R, Papanikolaou X, Grazziutti M, Cottler-Fox M, Petty N, Steward D, Panozzo S, Bailey C, Hoering A, Crowley J, Sawyer J, Morgan G, Barlogie B, van Rhee F. Adverse Metaphase Cytogenetics Can Be Overcome by Adding Bortezomib and Thalidomide to Fractionated Melphalan Transplants. Clin Cancer Res. 2017 Jun 01; 23(11):2665-2672. PMID: 27810902.
      View in: PubMed
    27. McDonald JE, Kessler MM, Gardner MW, Buros AF, Ntambi JA, Waheed S, van Rhee F, Zangari M, Heuck CJ, Petty N, Schinke C, Thanendrarajan S, Mitchell A, Hoering A, Barlogie B, Morgan GJ, Davies FE. Assessment of Total Lesion Glycolysis by 18F FDG PET/CT Significantly Improves Prognostic Value of GEP and ISS in Myeloma. Clin Cancer Res. 2017 Apr 15; 23(8):1981-1987. PMID: 27698001.
      View in: PubMed
    28. Calvert PA, Northridge DB, Malik IS, Shapiro L, Ludman P, Qureshi SA, Mullen M, Henderson R, Turner M, Been M, Walsh KP, Casserly I, Morrison L, Walker NL, Thomson J, Spence MS, Mahadevan VS, Hoye A, MacCarthy PA, Daniels MJ, Clift P, Davies WR, Adamson PD, Morgan G, Aggarwal SK, Ismail Y, Ormerod JO, Khan HR, Chandran SS, de Giovanni J, Rana BS, Ormerod O, Hildick-Smith D. Percutaneous Device Closure of Paravalvular Leak: Combined Experience From the United Kingdom and Ireland. Circulation. 2016 Sep 27; 134(13):934-44. PMID: 27587432.
      View in: PubMed
    29. Morgan GJ, Kelly JW. The Kinetic Stability of a Full-Length Antibody Light Chain Dimer Determines whether Endoproteolysis Can Release Amyloidogenic Variable Domains. J Mol Biol. 2016 Oct 23; 428(21):4280-4297. PMID: 27569045.
      View in: PubMed
    30. Husain J, Praichasilchai P, Gilbert Y, Qureshi SA, Morgan GJ. Early European experience with the Venus P-valve®: filling the gap in percutaneous pulmonary valve implantation. EuroIntervention. 2016 Aug 05; 12(5):e643-51. PMID: 27497365.
      View in: PubMed
    31. Sriskandarajah P, Pawlyn C, Mohammed K, Dearden CE, Davies FE, Morgan GJ, Boyd KD, Kaiser MF. The efficacy and tolerability of pomalidomide in relapsed/refractory myeloma patients in a "real-world" study: the Royal Marsden Hospital experience. Leuk Lymphoma. 2017 Feb; 58(2):494-497. PMID: 27439571.
      View in: PubMed
    32. Mitchell JS, Li N, Weinhold N, Försti A, Ali M, van Duin M, Thorleifsson G, Johnson DC, Chen B, Halvarsson BM, Gudbjartsson DF, Kuiper R, Stephens OW, Bertsch U, Broderick P, Campo C, Einsele H, Gregory WA, Gullberg U, Henrion M, Hillengass J, Hoffmann P, Jackson GH, Johnsson E, Jöud M, Kristinsson SY, Lenhoff S, Lenive O, Mellqvist UH, Migliorini G, Nahi H, Nelander S, Nickel J, Nöthen MM, Rafnar T, Ross FM, da Silva Filho MI, Swaminathan B, Thomsen H, Turesson I, Vangsted A, Vogel U, Waage A, Walker BA, Wihlborg AK, Broyl A, Davies FE, Thorsteinsdottir U, Langer C, Hansson M, Kaiser M, Sonneveld P, Stefansson K, Morgan GJ, Goldschmidt H, Hemminki K, Nilsson B, Houlston RS. Genome-wide association study identifies multiple susceptibility loci for multiple myeloma. Nat Commun. 2016 Jul 01; 7:12050. PMID: 27363682; PMCID: PMC4932178.
    33. Morgan GJ. Occlutech® muscular ventricular septal defect device: the first reported human use. Cardiol Young. 2016 Oct; 26(7):1448-51. PMID: 27329258.
      View in: PubMed
    34. Mikulasova A, Smetana J, Wayhelova M, Janyskova H, Sandecka V, Kufova Z, Almasi M, Jarkovsky J, Gregora E, Kessler P, Wrobel M, Walker BA, Wardell CP, Morgan GJ, Hajek R, Kuglik P. Genomewide profiling of copy-number alteration in monoclonal gammopathy of undetermined significance. Eur J Haematol. 2016 Dec; 97(6):568-575. PMID: 27157252.
      View in: PubMed
    35. Pawlyn C, Kaiser MF, Heuck C, Melchor L, Wardell CP, Murison A, Chavan SS, Johnson DC, Begum DB, Dahir NM, Proszek PZ, Cairns DA, Boyle EM, Jones JR, Cook G, Drayson MT, Owen RG, Gregory WM, Jackson GH, Barlogie B, Davies FE, Walker BA, Morgan GJ. The Spectrum and Clinical Impact of Epigenetic Modifier Mutations in Myeloma. Clin Cancer Res. 2016 Dec 01; 22(23):5783-5794. PMID: 27235425.
      View in: PubMed
    36. Dimopoulos MA, Palumbo A, Corradini P, Cavo M, Delforge M, Di Raimondo F, Weisel KC, Oriol A, Hansson M, Vacca A, Blanchard MJ, Goldschmidt H, Doyen C, Kaiser M, Petrini M, Anttila P, Cafro AM, Raymakers R, San-Miguel J, de Arriba F, Knop S, Röllig C, Ocio EM, Morgan G, Miller N, Simcock M, Peluso T, Herring J, Sternas L, Zaki MH, Moreau P. Safety and efficacy of pomalidomide plus low-dose dexamethasone in STRATUS (MM-010): a phase 3b study in refractory multiple myeloma. Blood. 2016 Jul 28; 128(4):497-503. PMID: 27226434; PMCID: PMC5009959.
    37. Morgan GJ, Qureshi SA. The diagnosis and interventional management of pulmonary arteriovenous malformations. EuroIntervention. 2016 May 17; 12 Suppl X:X24-X27. PMID: 27174107.
      View in: PubMed
    38. Murphy M, Austin C, Bapat V, Morgan GJ. Use of an Edwards Sapien S3 valve to replace a dysfunctional mechanical mitral valve in an 11-year old boy: another small step for surgical and interventional collaboration. Eur J Cardiothorac Surg. 2016 Sep; 50(3):577-9. PMID: 26994169.
      View in: PubMed
    39. Thanendrarajan S, Davies FE, Morgan GJ, Schinke C, Mathur P, Heuck CJ, Zangari M, Epstein J, Yaccoby S, Weinhold N, Barlogie B, van Rhee F. Monoclonal antibody therapy in multiple myeloma: where do we stand and where are we going? Immunotherapy. 2016; 8(3):367-84. PMID: 26888183.
      View in: PubMed
    40. Wu SP, Pfeiffer RM, Ahn IE, Mailankody S, Sonneveld P, van Duin M, Munshi NC, Walker BA, Morgan G, Landgren O. Impact of Genes Highly Correlated with MMSET Myeloma on the Survival of Non-MMSET Myeloma Patients. Clin Cancer Res. 2016 Aug 15; 22(16):4039-44. PMID: 26847058.
      View in: PubMed
    41. Calura E, Bisognin A, Manzoni M, Todoerti K, Taiana E, Sales G, Morgan GJ, Tonon G, Amodio N, Tassone P, Neri A, Agnelli L, Romualdi C, Bortoluzzi S. Disentangling the microRNA regulatory milieu in multiple myeloma: integrative genomics analysis outlines mixed miRNA-TF circuits and pathway-derived networks modulated in t(4;14) patients. Oncotarget. 2016 Jan 19; 7(3):2367-78. PMID: 26496024; PMCID: PMC4823041.
    42. Johnson DC, Weinhold N, Mitchell JS, Chen B, Kaiser M, Begum DB, Hillengass J, Bertsch U, Gregory WA, Cairns D, Jackson GH, Försti A, Nickel J, Hoffmann P, Nöethen MM, Stephens OW, Barlogie B, Davis FE, Hemminki K, Goldschmidt H, Houlston RS, Morgan GJ. Genome-wide association study identifies variation at 6q25.1 associated with survival in multiple myeloma. Nat Commun. 2016 Jan 08; 7:10290. PMID: 26743840; PMCID: PMC4729868.
    43. Meißner T, Seckinger A, Hemminki K, Bertsch U, Foersti A, Haenel M, Duering J, Salwender H, Goldschmidt H, Morgan GJ, Hose D, Weinhold N. Profound impact of sample processing delay on gene expression of multiple myeloma plasma cells. BMC Med Genomics. 2015 Dec 30; 8:85. PMID: 26714877; PMCID: PMC4696100.
    44. Andreotti G, Katz M, Hoering A, Van Ness B, Crowley J, Morgan G, Hoover RN, Baris D, Durie B. Risk of multiple myeloma in a case-spouse study. Leuk Lymphoma. 2016; 57(6):1450-9. PMID: 26422532.
      View in: PubMed
    45. de Tute RM, Rawstron AC, Gregory WM, Child JA, Davies FE, Bell SE, Cook G, Szubert AJ, Drayson MT, Jackson GH, Morgan GJ, Owen RG. Minimal residual disease following autologous stem cell transplant in myeloma: impact on outcome is independent of induction regimen. Haematologica. 2016 Feb; 101(2):e69-71. PMID: 26471484; PMCID: PMC4938335.
    46. Murphy MO, Bellsham-Revell H, Morgan GJ, Krasemann T, Rosenthal E, Qureshi SA, Salih C, Austin CB, Anderson DR. Hybrid Procedure for Neonates With Hypoplastic Left Heart Syndrome at High-Risk for Norwood: Midterm Outcomes. Ann Thorac Surg. 2015 Dec; 100(6):2286-90; discussion 2291-2. PMID: 26433522.
      View in: PubMed
    47. Peterson EA, Bauer MA, Chavan SS, Ashby C, Weinhold N, Heuck CJ, Morgan GJ, Johann DJ. Enhancing cancer clonality analysis with integrative genomics. BMC Bioinformatics. 2015; 16 Suppl 13:S7. PMID: 26424171; PMCID: PMC4597064.
    48. Kuiper R, van Duin M, van Vliet MH, Broijl A, van der Holt B, El Jarari L, van Beers EH, Mulligan G, Avet-Loiseau H, Gregory WM, Morgan G, Goldschmidt H, Lokhorst HM, Sonneveld P. Prediction of high- and low-risk multiple myeloma based on gene expression and the International Staging System. Blood. 2015 Oct 22; 126(17):1996-2004. PMID: 26330243; PMCID: PMC4616233.
    49. Rafiq I, Morgan G, Silva Vieira M, Qureshi S, Hussain T. Chronic Occlusion of the Superior Vena Cava Resulting in Cyanosis in an Adult: Unusual Case Highlighting the Value of Collaboration Between Adult and Congenital Cardiology Services. Circ Cardiovasc Interv. 2015 Sep; 8(9):e002163. PMID: 26286739.
      View in: PubMed
    50. Walker BA, Boyle EM, Wardell CP, Murison A, Begum DB, Dahir NM, Proszek PZ, Johnson DC, Kaiser MF, Melchor L, Aronson LI, Scales M, Pawlyn C, Mirabella F, Jones JR, Brioli A, Mikulasova A, Cairns DA, Gregory WM, Quartilho A, Drayson MT, Russell N, Cook G, Jackson GH, Leleu X, Davies FE, Morgan GJ. Mutational Spectrum, Copy Number Changes, and Outcome: Results of a Sequencing Study of Patients With Newly Diagnosed Myeloma. J Clin Oncol. 2015 Nov 20; 33(33):3911-20. PMID: 26282654.
      View in: PubMed
    51. Di Martino MT, Guzzi PH, Caracciolo D, Agnelli L, Neri A, Walker BA, Morgan GJ, Cannataro M, Tassone P, Tagliaferri P. Integrated analysis of microRNAs, transcription factors and target genes expression discloses a specific molecular architecture of hyperdiploid multiple myeloma. Oncotarget. 2015 Aug 07; 6(22):19132-47. PMID: 26056083; PMCID: PMC4662480.
    52. Palumbo A, Avet-Loiseau H, Oliva S, Lokhorst HM, Goldschmidt H, Rosinol L, Richardson P, Caltagirone S, Lahuerta JJ, Facon T, Bringhen S, Gay F, Attal M, Passera R, Spencer A, Offidani M, Kumar S, Musto P, Lonial S, Petrucci MT, Orlowski RZ, Zamagni E, Morgan G, Dimopoulos MA, Durie BG, Anderson KC, Sonneveld P, San Miguel J, Cavo M, Rajkumar SV, Moreau P. Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group. J Clin Oncol. 2015 Sep 10; 33(26):2863-9. PMID: 26240224; PMCID: PMC4846284.
    53. Mitchell JS, Johnson DC, Litchfield K, Broderick P, Weinhold N, Davies FE, Gregory WA, Jackson GH, Kaiser M, Morgan GJ, Houlston RS. Implementation of genome-wide complex trait analysis to quantify the heritability in multiple myeloma. Sci Rep. 2015 Jul 24; 5:12473. PMID: 26208354; PMCID: PMC4513545.
    54. Smith EM, Zhang L, Walker BA, Davenport EL, Aronson LI, Krige D, Hooftman L, Drummond AH, Morgan GJ, Davies FE. The combination of HDAC and aminopeptidase inhibitors is highly synergistic in myeloma and leads to disruption of the NF?B signalling pathway. Oncotarget. 2015 Jul 10; 6(19):17314-27. PMID: 26015393; PMCID: PMC4627310.
    55. Khan R, Dhodapkar M, Rosenthal A, Heuck C, Papanikolaou X, Qu P, van Rhee F, Zangari M, Jethava Y, Epstein J, Yaccoby S, Hoering A, Crowley J, Petty N, Bailey C, Morgan G, Barlogie B. Four genes predict high risk of progression from smoldering to symptomatic multiple myeloma (SWOG S0120). Haematologica. 2015 Sep; 100(9):1214-21. PMID: 26022710; PMCID: PMC4800692.
    56. Sawyer JR, Tian E, Heuck CJ, Johann DJ, Epstein J, Swanson CM, Lukacs JL, Binz RL, Johnson M, Sammartino G, Zangari M, Davies FE, van Rhee F, Morgan GJ, Barlogie B. Evidence of an epigenetic origin for high-risk 1q21 copy number aberrations in multiple myeloma. Blood. 2015 Jun 11; 125(24):3756-9. PMID: 25943786; PMCID: PMC4463736.
    57. Walker BA, Wardell CP, Murison A, Boyle EM, Begum DB, Dahir NM, Proszek PZ, Melchor L, Pawlyn C, Kaiser MF, Johnson DC, Qiang YW, Jones JR, Cairns DA, Gregory WM, Owen RG, Cook G, Drayson MT, Jackson GH, Davies FE, Morgan GJ. APOBEC family mutational signatures are associated with poor prognosis translocations in multiple myeloma. Nat Commun. 2015 Apr 23; 6:6997. PMID: 25904160; PMCID: PMC4568299.
    58. Schey S, Brown SR, Tillotson AL, Yong K, Williams C, Davies F, Morgan G, Cavenagh J, Cook G, Cook M, Orti G, Morris C, Sherratt D, Flanagan L, Gregory W, Cavet J. Bendamustine, thalidomide and dexamethasone combination therapy for relapsed/refractory myeloma patients: results of the MUKone randomized dose selection trial. Br J Haematol. 2015 Aug; 170(3):336-48. PMID: 25891006.
      View in: PubMed
    59. Bright MD, Itzhak DN, Wardell CP, Morgan GJ, Davies FE. Cleavage of BLOC1S1 mRNA by IRE1 Is Sequence Specific, Temporally Separate from XBP1 Splicing, and Dispensable for Cell Viability under Acute Endoplasmic Reticulum Stress. Mol Cell Biol. 2015 Jun; 35(12):2186-202. PMID: 25870107; PMCID: PMC4438243.
    60. Goreczny S, Qureshi S, Rosenthal E, Krasemann T, Bedair R, Salih C, Austin C, Anderson D, Morgan GJ. Self-expanding stent implantation in arterial duct during hybrid palliation of hypoplastic left heart syndrome: midterm experience with a specially designed stent. EuroIntervention. 2015 Mar; 10(11):1318-25. PMID: 25631369.
      View in: PubMed
    61. Stein CK, Qu P, Epstein J, Buros A, Rosenthal A, Crowley J, Morgan G, Barlogie B. Removing batch effects from purified plasma cell gene expression microarrays with modified ComBat. BMC Bioinformatics. 2015 Feb 25; 16:63. PMID: 25887219; PMCID: PMC4355992.
    62. Kang SL, Tometzki A, Caputo M, Morgan G, Parry A, Martin R. Longer-term outcome of perventricular device closure of muscular ventricular septal defects in children. Catheter Cardiovasc Interv. 2015 May; 85(6):998-1005. PMID: 25573696.
      View in: PubMed
    63. Rawstron AC, Gregory WM, de Tute RM, Davies FE, Bell SE, Drayson MT, Cook G, Jackson GH, Morgan GJ, Child JA, Owen RG. Minimal residual disease in myeloma by flow cytometry: independent prediction of survival benefit per log reduction. Blood. 2015 Mar 19; 125(12):1932-5. PMID: 25645353; PMCID: PMC4375716.
    64. Andersen JP, Bøgsted M, Dybkær K, Mellqvist UH, Morgan GJ, Goldschmidt H, Dimopoulos MA, Einsele H, San Miguel J, Palumbo A, Sonneveld P, Johnsen HE. Global myeloma research clusters, output, and citations: a bibliometric mapping and clustering analysis. PLoS One. 2015; 10(1):e0116966. PMID: 25629620; PMCID: PMC4309532.
    65. Weinhold N, Meissner T, Johnson DC, Seckinger A, Moreaux J, Försti A, Chen B, Nickel J, Chubb D, Rawstron AC, Doughty C, Dahir NB, Begum DB, Young K, Walker BA, Hoffmann P, Nöthen MM, Davies FE, Klein B, Goldschmidt H, Morgan GJ, Houlston RS, Hose D, Hemminki K. The 7p15.3 (rs4487645) association for multiple myeloma shows strong allele-specific regulation of the MYC-interacting gene CDCA7L in malignant plasma cells. Haematologica. 2015 Mar; 100(3):e110-3. PMID: 25480495; PMCID: PMC4349291.
    66. Pawlyn C, Melchor L, Murison A, Wardell CP, Brioli A, Boyle EM, Kaiser MF, Walker BA, Begum DB, Dahir NB, Proszek P, Gregory WM, Drayson MT, Jackson GH, Ross FM, Davies FE, Morgan GJ. Coexistent hyperdiploidy does not abrogate poor prognosis in myeloma with adverse cytogenetics and may precede IGH translocations. Blood. 2015 Jan 29; 125(5):831-40. PMID: 25428216; PMCID: PMC4327151.
    67. Morgan G, Palumbo A, Dhanasiri S, Lee D, Weisel K, Facon T, Delforge M, Oriol A, Zaki M, Yu X, Sternas L, Jacques C, Akehurst R, Offner F, Dimopoulos MA. Overall survival of relapsed and refractory multiple myeloma patients after adjusting for crossover in the MM-003 trial for pomalidomide plus low-dose dexamethasone. Br J Haematol. 2015 Mar; 168(6):820-3. PMID: 25403264.
      View in: PubMed
    68. Morgan GJ, van Rhee F. Haematological cancer: Optimizing the treatment of multiple myeloma. Nat Rev Clin Oncol. 2014 Dec; 11(12):686-8. PMID: 25348792.
      View in: PubMed
    69. Tornatore L, Sandomenico A, Raimondo D, Low C, Rocci A, Tralau-Stewart C, Capece D, D'Andrea D, Bua M, Boyle E, van Duin M, Zoppoli P, Jaxa-Chamiec A, Thotakura AK, Dyson J, Walker BA, Leonardi A, Chambery A, Driessen C, Sonneveld P, Morgan G, Palumbo A, Tramontano A, Rahemtulla A, Ruvo M, Franzoso G. Cancer-selective targeting of the NF-?B survival pathway with GADD45ß/MKK7 inhibitors. Cancer Cell. 2014 Oct 13; 26(4):495-508. PMID: 25314077; PMCID: PMC4197335.
    70. Pawlyn C, Khan MS, Muls A, Sriskandarajah P, Kaiser MF, Davies FE, Morgan GJ, Andreyev HJ. Lenalidomide-induced diarrhea in patients with myeloma is caused by bile acid malabsorption that responds to treatment. Blood. 2014 Oct 09; 124(15):2467-8. PMID: 25301337.
      View in: PubMed
    71. Barlogie B, Mitchell A, van Rhee F, Epstein J, Morgan GJ, Crowley J. Curing myeloma at last: defining criteria and providing the evidence. Blood. 2014 Nov 13; 124(20):3043-51. PMID: 25293776; PMCID: PMC4231416.
    72. Boyle EM, Proszek PZ, Kaiser MF, Begum D, Dahir N, Savola S, Wardell CP, Leleu X, Ross FM, Chiecchio L, Cook G, Drayson MT, Owen RG, Ashcroft JM, Jackson GH, Anthony Child J, Davies FE, Walker BA, Morgan GJ. A molecular diagnostic approach able to detect the recurrent genetic prognostic factors typical of presenting myeloma. Genes Chromosomes Cancer. 2015 Feb; 54(2):91-8. PMID: 25287954; PMCID: PMC4310140.
    73. Brioli A, Melchor L, Walker BA, Davies FE, Morgan GJ. Biology and treatment of myeloma. Clin Lymphoma Myeloma Leuk. 2014 Sep; 14 Suppl:S65-70. PMID: 25486959.
      View in: PubMed
    74. Wu P, Walker BA, Broyl A, Kaiser M, Johnson DC, Kuiper R, van Duin M, Gregory WM, Davies FE, Brewer D, Hose D, Sonneveld P, Morgan GJ. A gene expression based predictor for high risk myeloma treated with intensive therapy and autologous stem cell rescue. Leuk Lymphoma. 2015 Mar; 56(3):594-601. PMID: 24913504; PMCID: PMC4444991.
    75. Ludwig H, Sonneveld P, Davies F, Bladé J, Boccadoro M, Cavo M, Morgan G, de la Rubia J, Delforge M, Dimopoulos M, Einsele H, Facon T, Goldschmidt H, Moreau P, Nahi H, Plesner T, San-Miguel J, Hajek R, Sondergeld P, Palumbo A. European perspective on multiple myeloma treatment strategies in 2014. Oncologist. 2014 Aug; 19(8):829-44. PMID: 25063227; PMCID: PMC4122482.
    76. Glavey SV, Manier S, Natoni A, Sacco A, Moschetta M, Reagan MR, Murillo LS, Sahin I, Wu P, Mishima Y, Zhang Y, Zhang W, Zhang Y, Morgan G, Joshi L, Roccaro AM, Ghobrial IM, O'Dwyer ME. The sialyltransferase ST3GAL6 influences homing and survival in multiple myeloma. Blood. 2014 Sep 11; 124(11):1765-76. PMID: 25061176; PMCID: PMC4162107.
    77. Mirabella F, Murison A, Aronson LI, Wardell CP, Thompson AJ, Hanrahan SJ, Fok JH, Pawlyn C, Kaiser MF, Walker BA, Davies FE, Morgan GJ. A novel functional role for MMSET in RNA processing based on the link between the REIIBP isoform and its interaction with the SMN complex. PLoS One. 2014; 9(6):e99493. PMID: 24923560; PMCID: PMC4055699.
    78. Pratt G, Jenner M, Owen R, Snowden JA, Ashcroft J, Yong K, Feyler S, Morgan G, Cavenagh J, Cook G, Low E, Stern S, Behrens J, Davies F, Bird J. Updates to the guidelines for the diagnosis and management of multiple myeloma. Br J Haematol. 2014 Oct; 167(1):131-3. PMID: 24801672.
      View in: PubMed
    79. Brioli A, Melchor L, Titley I, Vijayaraghavan G, Stephens C, Zeisig A, Pawlyn C, Cavo M, Morilla R, Davies FE, Morgan GJ. The impact of long-term lenalidomide exposure on the cellular composition of bone marrow. Leuk Lymphoma. 2014 Nov; 55(11):2665-8. PMID: 24660850.
      View in: PubMed
    80. Morgan GJ. Jumping translocations and high-risk myeloma. Blood. 2014 Apr 17; 123(16):2442-3. PMID: 24744247.
      View in: PubMed
    81. Brioli A, Giles H, Pawlyn C, Campbell JP, Kaiser MF, Melchor L, Jackson GH, Gregory WM, Owen RG, Child JA, Davies FE, Cavo M, Drayson MT, Morgan GJ. Serum free immunoglobulin light chain evaluation as a marker of impact from intraclonal heterogeneity on myeloma outcome. Blood. 2014 May 29; 123(22):3414-9. PMID: 24733348.
      View in: PubMed
    82. Pawlyn C, Kaiser MF, Davies FE, Morgan GJ. Current and potential epigenetic targets in multiple myeloma. Epigenomics. 2014 Apr; 6(2):215-28. PMID: 24811790.
      View in: PubMed
    83. Boyle EM, Davies FE, Leleu X, Morgan GJ. Understanding the multiple biological aspects leading to myeloma. Haematologica. 2014 Apr; 99(4):605-12. PMID: 24688108; PMCID: PMC3971069.
    84. Jackson GH, Morgan GJ, Davies FE, Wu P, Gregory WM, Bell SE, Szubert AJ, Navarro Coy N, Drayson MT, Owen RG, Feyler S, Ashcroft AJ, Ross FM, Byrne J, Roddie H, Rudin C, Boyd KD, Osborne WL, Cook G, Child JA. Osteonecrosis of the jaw and renal safety in patients with newly diagnosed multiple myeloma: Medical Research Council Myeloma IX Study results. Br J Haematol. 2014 Jul; 166(1):109-17. PMID: 24673708.
      View in: PubMed
    85. van de Donk NW, Palumbo A, Johnsen HE, Engelhardt M, Gay F, Gregersen H, Hajek R, Kleber M, Ludwig H, Morgan G, Musto P, Plesner T, Sezer O, Terpos E, Waage A, Zweegman S, Einsele H, Sonneveld P, Lokhorst HM. The clinical relevance and management of monoclonal gammopathy of undetermined significance and related disorders: recommendations from the European Myeloma Network. Haematologica. 2014 Jun; 99(6):984-96. PMID: 24658815; PMCID: PMC4040895.
    86. Brioli A, Melchor L, Cavo M, Morgan GJ. The impact of intra-clonal heterogeneity on the treatment of multiple myeloma. Br J Haematol. 2014 May; 165(4):441-54. PMID: 24580032.
      View in: PubMed
    87. Itzhak D, Bright M, McAndrew P, Mirza A, Newbatt Y, Strover J, Widya M, Thompson A, Morgan G, Collins I, Davies F. Multiple autophosphorylations significantly enhance the endoribonuclease activity of human inositol requiring enzyme 1a. BMC Biochem. 2014 Feb 13; 15:3. PMID: 24524643; PMCID: PMC3928614.
    88. Engelhardt M, Terpos E, Kleber M, Gay F, Wäsch R, Morgan G, Cavo M, van de Donk N, Beilhack A, Bruno B, Johnsen HE, Hajek R, Driessen C, Ludwig H, Beksac M, Boccadoro M, Straka C, Brighen S, Gramatzki M, Larocca A, Lokhorst H, Magarotto V, Morabito F, Dimopoulos MA, Einsele H, Sonneveld P, Palumbo A. European Myeloma Network recommendations on the evaluation and treatment of newly diagnosed patients with multiple myeloma. Haematologica. 2014 Feb; 99(2):232-42. PMID: 24497560; PMCID: PMC3912952.
    89. Kang SL, Morgan G, Forsey J, Tometzki A, Martin R. Long-term clinical experience with Amplatzer Ductal Occluder II for closure of the persistent arterial duct in children. Catheter Cardiovasc Interv. 2014 Jun 01; 83(7):1102-8. PMID: 24403100.
      View in: PubMed
    90. Weinhold N, Johnson DC, Rawstron AC, Försti A, Doughty C, Vijayakrishnan J, Broderick P, Dahir NB, Begum DB, Hosking FJ, Yong K, Walker BA, Hoffmann P, Mühleisen TW, Langer C, Dörner E, Jöckel KH, Eisele L, Nöthen MM, Hose D, Davies FE, Goldschmidt H, Morgan GJ, Hemminki K, Houlston RS. Inherited genetic susceptibility to monoclonal gammopathy of unknown significance. Blood. 2014 Apr 17; 123(16):2513-7; quiz 2593. PMID: 24449210.
      View in: PubMed
    91. Giles SL, Messiou C, Collins DJ, Morgan VA, Simpkin CJ, West S, Davies FE, Morgan GJ, deSouza NM. Whole-body diffusion-weighted MR imaging for assessment of treatment response in myeloma. Radiology. 2014 Jun; 271(3):785-94. PMID: 24475858.
      View in: PubMed
    92. Rawstron AC, Child JA, de Tute RM, Davies FE, Gregory WM, Bell SE, Szubert AJ, Navarro Coy N, Drayson MT, Feyler S, Ross FM, Cook G, Jackson GH, Morgan GJ, Owen RG. Reply to M. Roschewski et al. J Clin Oncol. 2014 Feb 10; 32(5):476-7. PMID: 24419132.
      View in: PubMed
    93. Palumbo A, Rajkumar SV, San Miguel JF, Larocca A, Niesvizky R, Morgan G, Landgren O, Hajek R, Einsele H, Anderson KC, Dimopoulos MA, Richardson PG, Cavo M, Spencer A, Stewart AK, Shimizu K, Lonial S, Sonneveld P, Durie BG, Moreau P, Orlowski RZ. International Myeloma Working Group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantation. J Clin Oncol. 2014 Feb 20; 32(6):587-600. PMID: 24419113; PMCID: PMC3918540.
    94. Brioli A, Morgan GJ, Durie B, Zamagni E. The utility of newer imaging techniques as predictors of clinical outcomes in multiple myeloma. Expert Rev Hematol. 2014 Feb; 7(1):13-6. PMID: 24428518.
      View in: PubMed
    95. Bøgsted M, Bilgrau AE, Wardell CP, Bertsch U, Schmitz A, Bødker JS, Kjeldsen MK, Goldschmidt H, Morgan GJ, Dybkaer K, Johnsen HE. Proof of the concept to use a malignant B cell line drug screen strategy for identification and weight of melphalan resistance genes in multiple myeloma. PLoS One. 2013; 8(12):e83252. PMID: 24376673; PMCID: PMC3869769.
    96. Landgren O, Morgan GJ. Biologic frontiers in multiple myeloma: from biomarker identification to clinical practice. Clin Cancer Res. 2014 Feb 15; 20(4):804-13. PMID: 24270684.
      View in: PubMed
    97. Kaplan LD, Deitcher SR, Silverman JA, Morgan G. Phase II study of vincristine sulfate liposome injection (Marqibo) and rituximab for patients with relapsed and refractory diffuse large B-Cell lymphoma or mantle cell lymphoma in need of palliative therapy. Clin Lymphoma Myeloma Leuk. 2014 Feb; 14(1):37-42. PMID: 24252360.
      View in: PubMed
    98. Morgan GJ, Davies FE, Gregory WM, Bell SE, Szubert AJ, Cook G, Drayson MT, Owen RG, Ross FM, Jackson GH, Child JA. Long-term follow-up of MRC Myeloma IX trial: Survival outcomes with bisphosphonate and thalidomide treatment. Clin Cancer Res. 2013 Nov 01; 19(21):6030-8. PMID: 23995858.
      View in: PubMed
    99. Larocca A, Child JA, Cook G, Jackson GH, Russell N, Szubert A, Gregory WM, Brioli A, Owen RG, Drayson MT, Wu P, Palumbo A, Boccadoro M, Davies FE, Morgan GJ. The impact of response on bone-directed therapy in patients with multiple myeloma. Blood. 2013 Oct 24; 122(17):2974-7. PMID: 23974194.
      View in: PubMed
    100. Morgan GJ. Transplants for the elderly in myeloma. Blood. 2013 Aug 22; 122(8):1332-4. PMID: 23970352.
      View in: PubMed
    101. Chubb D, Weinhold N, Broderick P, Chen B, Johnson DC, Försti A, Vijayakrishnan J, Migliorini G, Dobbins SE, Holroyd A, Hose D, Walker BA, Davies FE, Gregory WA, Jackson GH, Irving JA, Pratt G, Fegan C, Fenton JA, Neben K, Hoffmann P, Nöthen MM, Mühleisen TW, Eisele L, Ross FM, Straka C, Einsele H, Langer C, Dörner E, Allan JM, Jauch A, Morgan GJ, Hemminki K, Houlston RS, Goldschmidt H. Common variation at 3q26.2, 6p21.33, 17p11.2 and 22q13.1 influences multiple myeloma risk. Nat Genet. 2013 Oct; 45(10):1221-1225. PMID: 23955597.
      View in: PubMed
    102. Zhang L, Fok JJ, Mirabella F, Aronson LI, Fryer RA, Workman P, Morgan GJ, Davies FE. Hsp70 inhibition induces myeloma cell death via the intracellular accumulation of immunoglobulin and the generation of proteotoxic stress. Cancer Lett. 2013 Oct 01; 339(1):49-59. PMID: 23887058; PMCID: PMC3778988.
    103. Jordan S, Watkins A, Storey M, Allen SJ, Brooks CJ, Garaiova I, Heaven ML, Jones R, Plummer SF, Russell IT, Thornton CA, Morgan G. Volunteer bias in recruitment, retention, and blood sample donation in a randomised controlled trial involving mothers and their children at six months and two years: a longitudinal analysis. PLoS One. 2013; 8(7):e67912. PMID: 23874465; PMCID: PMC3706448.
    104. Walker BA, Wardell CP, Melchor L, Brioli A, Johnson DC, Kaiser MF, Mirabella F, Lopez-Corral L, Humphray S, Murray L, Ross M, Bentley D, Gutiérrez NC, Garcia-Sanz R, San Miguel J, Davies FE, Gonzalez D, Morgan GJ. Intraclonal heterogeneity is a critical early event in the development of myeloma and precedes the development of clinical symptoms. Leukemia. 2014 Feb; 28(2):384-390. PMID: 23817176; PMCID: PMC3916874.
    105. Morgan GJ, Davies FE. Role of thalidomide in the treatment of patients with multiple myeloma. Crit Rev Oncol Hematol. 2013 Oct; 88 Suppl 1:S14-22. PMID: 23827438.
      View in: PubMed
    106. Walker BA, Wardell CP, Ross FM, Morgan GJ. Identification of a novel t(7;14) translocation in multiple myeloma resulting in overexpression of EGFR. Genes Chromosomes Cancer. 2013 Sep; 52(9):817-22. PMID: 23765574.
      View in: PubMed
    107. Rawstron AC, Child JA, de Tute RM, Davies FE, Gregory WM, Bell SE, Szubert AJ, Navarro-Coy N, Drayson MT, Feyler S, Ross FM, Cook G, Jackson GH, Morgan GJ, Owen RG. Minimal residual disease assessed by multiparameter flow cytometry in multiple myeloma: impact on outcome in the Medical Research Council Myeloma IX Study. J Clin Oncol. 2013 Jul 10; 31(20):2540-7. PMID: 23733781.
      View in: PubMed
    108. Morgan GJ, Benson L. Reducing air embolism and improving accuracy during pediatric wedge measurements. J Invasive Cardiol. 2013 Jun; 25(6):320. PMID: 23735362.
      View in: PubMed
    109. Wu P, Agnelli L, Walker BA, Todoerti K, Lionetti M, Johnson DC, Kaiser M, Mirabella F, Wardell C, Gregory WM, Davies FE, Brewer D, Neri A, Morgan GJ. Improved risk stratification in myeloma using a microRNA-based classifier. Br J Haematol. 2013 Aug; 162(3):348-59. PMID: 23718138.
      View in: PubMed
    110. Kaiser MF, Johnson DC, Wu P, Walker BA, Brioli A, Mirabella F, Wardell CP, Melchor L, Davies FE, Morgan GJ. Global methylation analysis identifies prognostically important epigenetically inactivated tumor suppressor genes in multiple myeloma. Blood. 2013 Jul 11; 122(2):219-26. PMID: 23699600; PMCID: PMC3709654.
    111. Pieles GE, Ofoe V, Morgan GJ. Severe left main coronary artery stenosis with abnormal branching pattern in a patient with mild supravalvar aortic stenosis and Williams-Beuren syndrome. Congenit Heart Dis. 2014 May-Jun; 9(3):E85-9. PMID: 23701710.
      View in: PubMed
    112. Terpos E, Morgan G, Dimopoulos MA, Drake MT, Lentzsch S, Raje N, Sezer O, García-Sanz R, Shimizu K, Turesson I, Reiman T, Jurczyszyn A, Merlini G, Spencer A, Leleu X, Cavo M, Munshi N, Rajkumar SV, Durie BG, Roodman GD. International Myeloma Working Group recommendations for the treatment of multiple myeloma-related bone disease. J Clin Oncol. 2013 Jun 20; 31(18):2347-57. PMID: 23690408; PMCID: PMC4878084.
    113. Weinhold N, Johnson DC, Chubb D, Chen B, Försti A, Hosking FJ, Broderick P, Ma YP, Dobbins SE, Hose D, Walker BA, Davies FE, Kaiser MF, Li NL, Gregory WA, Jackson GH, Witzens-Harig M, Neben K, Hoffmann P, Nöthen MM, Mühleisen TW, Eisele L, Ross FM, Jauch A, Goldschmidt H, Houlston RS, Morgan GJ, Hemminki K. The CCND1 c.870G>A polymorphism is a risk factor for t(11;14)(q13;q32) multiple myeloma. Nat Genet. 2013 May; 45(5):522-525. PMID: 23502783.
      View in: PubMed
    114. Walker BA, Wardell CP, Johnson DC, Kaiser MF, Begum DB, Dahir NB, Ross FM, Davies FE, Gonzalez D, Morgan GJ. Characterization of IGH locus breakpoints in multiple myeloma indicates a subset of translocations appear to occur in pregerminal center B cells. Blood. 2013 Apr 25; 121(17):3413-9. PMID: 23435460.
      View in: PubMed
    115. Fryer RA, Graham TJ, Smith EM, Walker-Samuel S, Morgan GJ, Robinson SP, Davies FE. Characterization of a novel mouse model of multiple myeloma and its use in preclinical therapeutic assessment. PLoS One. 2013; 8(2):e57641. PMID: 23437401; PMCID: PMC3578800.
    116. Lodi A, Tiziani S, Khanim FL, Günther UL, Viant MR, Morgan GJ, Bunce CM, Drayson MT. Proton NMR-based metabolite analyses of archived serial paired serum and urine samples from myeloma patients at different stages of disease activity identifies acetylcarnitine as a novel marker of active disease. PLoS One. 2013; 8(2):e56422. PMID: 23431376; PMCID: PMC3576408.
    117. Brioli A, Boyd KD, Kaiser MF, Pawlyn C, Wu P, Gregory WM, Owen R, Ross FM, Jackson GH, Cavo M, Davies FE, Morgan GJ. Response and biological subtype of myeloma are independent prognostic factors and combine to define outcome after high-dose therapy. Br J Haematol. 2013 Apr; 161(2):291-4. PMID: 23356460.
      View in: PubMed
    118. Morgan GJ, Yim DL, Hayes AM, Martin RP, Hamilton MC, Stuart G. Imaging and percutaneous occlusion of a large aneurysm of the ductus arteriosus in an infant with Loeys-Dietz syndrome. Congenit Heart Dis. 2013 Nov-Dec; 8(6):E192-5. PMID: 23350955.
      View in: PubMed
    119. Brioli A, Kaiser MF, Pawlyn C, Wu P, Gregory WM, Owen R, Ross FM, Jackson GH, Cavo M, Davies FE, Morgan GJ. Biologically defined risk groups can be used to define the impact of thalidomide maintenance therapy in newly diagnosed multiple myeloma. Leuk Lymphoma. 2013 Sep; 54(9):1975-81. PMID: 23270579.
      View in: PubMed
    120. Dignan FL, Potter MN, Ethell ME, Taylor M, Lewis L, Brennan J, McNamara L, Evans SO, Riley U, Davies FE, Dearden CE, Morgan GJ, Shaw BE. High readmission rates are associated with a significant economic burden and poor outcome in patients with grade III/IV acute GvHD. Clin Transplant. 2013 Jan-Feb; 27(1):E56-63. PMID: 23278853.
      View in: PubMed
    121. Turner MS, Hamilton M, Morgan GJ, Martin RP. Percutaneous Closure of Post-Myocardial Infarction Ventricular Septal Defect: Patient Selection and Management. Interv Cardiol Clin. 2013 Jan; 2(1):173-180. PMID: 28581981.
      View in: PubMed
    122. Boyd KD, Pawlyn C, Morgan GJ, Davies FE. Understanding the molecular biology of myeloma and its therapeutic implications. Expert Rev Hematol. 2012 Dec; 5(6):603-17. PMID: 23216592.
      View in: PubMed
    123. Newbatt Y, Hardcastle A, McAndrew PC, Strover JA, Mirza A, Morgan GJ, Burke R, Davies FE, Collins I, van Montfort RL. Identification of autophosphorylation inhibitors of the inositol-requiring enzyme 1 alpha (IRE1a) by high-throughput screening using a DELFIA assay. J Biomol Screen. 2013 Mar; 18(3):298-308. PMID: 23139381.
      View in: PubMed
    124. Gonzalez D, Else M, Wren D, Usai M, Buhl AM, Parker A, Oscier D, Morgan G, Catovsky D. CLLU1 expression has prognostic value in chronic lymphocytic leukemia after first-line therapy in younger patients and in those with mutated IGHV genes. Haematologica. 2013 Feb; 98(2):274-8. PMID: 22899580; PMCID: PMC3561436.
    125. Walker BA, Wardell CP, Melchor L, Hulkki S, Potter NE, Johnson DC, Fenwick K, Kozarewa I, Gonzalez D, Lord CJ, Ashworth A, Davies FE, Morgan GJ. Intraclonal heterogeneity and distinct molecular mechanisms characterize the development of t(4;14) and t(11;14) myeloma. Blood. 2012 Aug 02; 120(5):1077-86. PMID: 22573403.
      View in: PubMed
    126. Morgan GJ, Walker BA, Davies FE. The genetic architecture of multiple myeloma. Nat Rev Cancer. 2012 Apr 12; 12(5):335-48. PMID: 22495321.
      View in: PubMed
    127. Morgan GJ, Davies FE, Gregory WM, Szubert AJ, Bell SE, Drayson MT, Owen RG, Ashcroft AJ, Jackson GH, Child JA. Effects of induction and maintenance plus long-term bisphosphonates on bone disease in patients with multiple myeloma: the Medical Research Council Myeloma IX Trial. Blood. 2012 Jun 07; 119(23):5374-83. PMID: 22498739.
      View in: PubMed
    128. Kozarewa I, Rosa-Rosa JM, Wardell CP, Walker BA, Fenwick K, Assiotis I, Mitsopoulos C, Zvelebil M, Morgan GJ, Ashworth A, Lord CJ, J C. A modified method for whole exome resequencing from minimal amounts of starting DNA. PLoS One. 2012; 7(3):e32617. PMID: 22403682; PMCID: PMC3293839.
    129. Delea TE, Rotter J, Taylor M, Chandiwana D, Bains M, El Ouagari K, Kaura S, Morgan GJ. Cost-effectiveness of zoledronic acid vs clodronic acid for newly-diagnosed multiple myeloma from the United Kingdom healthcare system perspective. J Med Econ. 2012; 15(3):454-64. PMID: 22316275.
      View in: PubMed
    130. Dimopoulos MA, Richardson PG, Brandenburg N, Yu Z, Weber DM, Niesvizky R, Morgan GJ. A review of second primary malignancy in patients with relapsed or refractory multiple myeloma treated with lenalidomide. Blood. 2012 Mar 22; 119(12):2764-7. PMID: 22323483.
      View in: PubMed
    131. Ludwig H, Durie BG, McCarthy P, Palumbo A, San Miguel J, Barlogie B, Morgan G, Sonneveld P, Spencer A, Andersen KC, Facon T, Stewart KA, Einsele H, Mateos MV, Wijermans P, Waage A, Beksac M, Richardson PG, Hulin C, Niesvizky R, Lokhorst H, Landgren O, Bergsagel PL, Orlowski R, Hinke A, Cavo M, Attal M. IMWG consensus on maintenance therapy in multiple myeloma. Blood. 2012 Mar 29; 119(13):3003-15. PMID: 22271445; PMCID: PMC3321864.
    132. Kleber M, Udi J, Metzke B, Terpos E, Roodmann GD, Morgan G, Dispenzieri A, Einsele H, Wäsch R, Engelhardt M. Challenging the current approaches to multiple myeloma- and other cancer-related bone diseases: from bisphosphonates to targeted therapy. Leuk Lymphoma. 2012 Jun; 53(6):1057-61. PMID: 22149167.
      View in: PubMed
    133. Morgan G, Johnsen HE, Goldschmidt H, Palumbo A, Cavo M, Sonneveld P, Miguel JS, Chim CS, Browne P, Einsele H, Waage A, Turesson I, Spencer A, Hajek R, Ludwig H, Hemminki K, Houlston R. MyelomA Genetics International Consortium. Leuk Lymphoma. 2012 May; 53(5):796-800. PMID: 22080755.
      View in: PubMed
    134. Locke FL, Morgan GJ. What is the evidence for the use of bisphosphonate therapy in newly diagnosed multiple myeloma patients lacking bone disease? Hematology Am Soc Hematol Educ Program. 2012; 2012:350-3. PMID: 23233603.
      View in: PubMed
    135. Morgan GJ, Kaiser MF. How to use new biology to guide therapy in multiple myeloma. Hematology Am Soc Hematol Educ Program. 2012; 2012:342-9. PMID: 23233602.
      View in: PubMed
    136. Broderick P, Chubb D, Johnson DC, Weinhold N, Försti A, Lloyd A, Olver B, Ma Y, Dobbins SE, Walker BA, Davies FE, Gregory WA, Childs JA, Ross FM, Jackson GH, Neben K, Jauch A, Hoffmann P, Mühleisen TW, Nöthen MM, Moebus S, Tomlinson IP, Goldschmidt H, Hemminki K, Morgan GJ, Houlston RS. Common variation at 3p22.1 and 7p15.3 influences multiple myeloma risk. Nat Genet. 2011 Nov 27; 44(1):58-61. PMID: 22120009.
      View in: PubMed
    137. Kassambara A, Hose D, Moreaux J, Walker BA, Protopopov A, Reme T, Pellestor F, Pantesco V, Jauch A, Morgan G, Goldschmidt H, Klein B. Genes with a spike expression are clustered in chromosome (sub)bands and spike (sub)bands have a powerful prognostic value in patients with multiple myeloma. Haematologica. 2012 Apr; 97(4):622-30. PMID: 22102711; PMCID: PMC3347668.
    138. Morgan GJ, Davies FE, Gregory WM, Bell SE, Szubert AJ, Navarro Coy N, Cook G, Feyler S, Johnson PR, Rudin C, Drayson MT, Owen RG, Ross FM, Russell NH, Jackson GH, Child JA. Cyclophosphamide, thalidomide, and dexamethasone as induction therapy for newly diagnosed multiple myeloma patients destined for autologous stem-cell transplantation: MRC Myeloma IX randomized trial results. Haematologica. 2012 Mar; 97(3):442-50. PMID: 22058209; PMCID: PMC3291601.
    139. Morgan GJ, Gregory WM, Davies FE, Bell SE, Szubert AJ, Brown JM, Coy NN, Cook G, Russell NH, Rudin C, Roddie H, Drayson MT, Owen RG, Ross FM, Jackson GH, Child JA. The role of maintenance thalidomide therapy in multiple myeloma: MRC Myeloma IX results and meta-analysis. Blood. 2012 Jan 05; 119(1):7-15. PMID: 22021371.
      View in: PubMed
    140. Boyd KD, Ross FM, Walker BA, Wardell CP, Tapper WJ, Chiecchio L, Dagrada G, Konn ZJ, Gregory WM, Jackson GH, Child JA, Davies FE, Morgan GJ. Mapping of chromosome 1p deletions in myeloma identifies FAM46C at 1p12 and CDKN2C at 1p32.3 as being genes in regions associated with adverse survival. Clin Cancer Res. 2011 Dec 15; 17(24):7776-84. PMID: 21994415.
      View in: PubMed
    141. Boyd KD, Ross FM, Tapper WJ, Chiecchio L, Dagrada G, Konn ZJ, Gonzalez D, Walker BA, Hockley SL, Wardell CP, Gregory WM, Child JA, Jackson GH, Davies FE, Morgan GJ. The clinical impact and molecular biology of del(17p) in multiple myeloma treated with conventional or thalidomide-based therapy. Genes Chromosomes Cancer. 2011 10; 50(10):765-74. PMID: 21961181.
      View in: PubMed
    142. Grey-Davies E, Bosworth JL, Boyd KD, Ebdon C, Saso R, Chitnavis D, Mercieca JE, Morgan GJ, Davies FE. Bendamustine, Thalidomide and Dexamethasone is an effective salvage regimen for advanced stage multiple myeloma. Br J Haematol. 2012 Feb; 156(4):552-5; author reply 555. PMID: 21950692.
      View in: PubMed
    143. Agnelli L, Forcato M, Ferrari F, Tuana G, Todoerti K, Walker BA, Morgan GJ, Lombardi L, Bicciato S, Neri A. The reconstruction of transcriptional networks reveals critical genes with implications for clinical outcome of multiple myeloma. Clin Cancer Res. 2011 Dec 01; 17(23):7402-12. PMID: 21890453.
      View in: PubMed
    144. Wu P, Walker BA, Brewer D, Gregory WM, Ashcroft J, Ross FM, Jackson GH, Child AJ, Davies FE, Morgan GJ. A gene expression-based predictor for myeloma patients at high risk of developing bone disease on bisphosphonate treatment. Clin Cancer Res. 2011 Oct 01; 17(19):6347-55. PMID: 21856767; PMCID: PMC3866998.
    145. Palumbo A, Bringhen S, Ludwig H, Dimopoulos MA, Bladé J, Mateos MV, Rosiñol L, Boccadoro M, Cavo M, Lokhorst H, Zweegman S, Terpos E, Davies F, Driessen C, Gimsing P, Gramatzki M, Hàjek R, Johnsen HE, Leal Da Costa F, Sezer O, Spencer A, Beksac M, Morgan G, Einsele H, San Miguel JF, Sonneveld P. Personalized therapy in multiple myeloma according to patient age and vulnerability: a report of the European Myeloma Network (EMN). Blood. 2011 Oct 27; 118(17):4519-29. PMID: 21841166.
      View in: PubMed
    146. Corthals SL, Kuiper R, Johnson DC, Sonneveld P, Hajek R, van der Holt B, Magrangeas F, Goldschmidt H, Morgan GJ, Avet-Loiseau H. Genetic factors underlying the risk of bortezomib induced peripheral neuropathy in multiple myeloma patients. Haematologica. 2011 Nov; 96(11):1728-32. PMID: 21791469; PMCID: PMC3208695.
    147. Morgan GJ, Child JA, Gregory WM, Szubert AJ, Cocks K, Bell SE, Navarro-Coy N, Drayson MT, Owen RG, Feyler S, Ashcroft AJ, Ross FM, Byrne J, Roddie H, Rudin C, Cook G, Jackson GH, Wu P, Davies FE. Effects of zoledronic acid versus clodronic acid on skeletal morbidity in patients with newly diagnosed multiple myeloma (MRC Myeloma IX): secondary outcomes from a randomised controlled trial. Lancet Oncol. 2011 Aug; 12(8):743-52. PMID: 21771568; PMCID: PMC3148431.
    148. Anoop P, Shaw BE, Riley U, Ethell ME, Taj M, Lancaster DL, Atra A, Saso R, Littlewood S, Mohammed K, Davies F, Treleaven J, Morgan GJ, Potter MN. Clinical profile and outcome of urotheliotropic viral haemorrhagic cystitis following haematopoietic stem cell transplantation: a 7-year tertiary centre analysis. Hematology. 2011 Jul; 16(4):213-20. PMID: 21756537.
      View in: PubMed
    149. Ishak KJ, Caro JJ, Drayson MT, Dimopoulos M, Weber D, Augustson B, Child JA, Knight R, Iqbal G, Dunn J, Shearer A, Morgan G. Adjusting for patient crossover in clinical trials using external data: a case study of lenalidomide for advanced multiple myeloma. Value Health. 2011 Jul-Aug; 14(5):672-8. PMID: 21839405.
      View in: PubMed
    150. Alvares CL, Schenk T, Hulkki S, Min T, Vijayaraghavan G, Yeung J, Gonzalez D, So CW, Greaves M, Titley I, Bartolovic K, Morgan G. Tyrosine kinase inhibitor insensitivity of non-cycling CD34+ human acute myeloid leukaemia cells with FMS-like tyrosine kinase 3 mutations. Br J Haematol. 2011 Aug; 154(4):457-65. PMID: 21689085.
      View in: PubMed
    151. Boyd KD, Ross FM, Chiecchio L, Dagrada G, Konn ZJ, Tapper WJ, Walker BA, Wardell CP, Gregory WM, Szubert AJ, Davies FE, Morgan GJ. Gender disparities in the tumor genetics and clinical outcome of multiple myeloma. Cancer Epidemiol Biomarkers Prev. 2011 Aug; 20(8):1703-7. PMID: 21680536; PMCID: PMC4545514.
    152. Morgan GJ, Davies FE, Gregory WM, Russell NH, Bell SE, Szubert AJ, Navarro Coy N, Cook G, Feyler S, Byrne JL, Roddie H, Rudin C, Drayson MT, Owen RG, Ross FM, Jackson GH, Child JA. Cyclophosphamide, thalidomide, and dexamethasone (CTD) as initial therapy for patients with multiple myeloma unsuitable for autologous transplantation. Blood. 2011 Aug 04; 118(5):1231-8. PMID: 21652683; PMCID: PMC3152492.
    153. Bird JM, Owen RG, D'Sa S, Snowden JA, Pratt G, Ashcroft J, Yong K, Cook G, Feyler S, Davies F, Morgan G, Cavenagh J, Low E, Behrens J. Guidelines for the diagnosis and management of multiple myeloma 2011. Br J Haematol. 2011 Jul; 154(1):32-75. PMID: 21569004.
      View in: PubMed
    154. Cook G, Liakopoulou E, Pearce R, Cavet J, Morgan GJ, Kirkland K, Lee J, Davies FE, Hall R, Rahemtulla A, Russell N, Marks DI. Factors influencing the outcome of a second autologous stem cell transplant (ASCT) in relapsed multiple myeloma: a study from the British Society of Blood and Marrow Transplantation Registry. Biol Blood Marrow Transplant. 2011 Nov; 17(11):1638-45. PMID: 21565277.
      View in: PubMed
    155. Gonzalez D, Martinez P, Wade R, Hockley S, Oscier D, Matutes E, Dearden CE, Richards SM, Catovsky D, Morgan GJ. Mutational status of the TP53 gene as a predictor of response and survival in patients with chronic lymphocytic leukemia: results from the LRF CLL4 trial. J Clin Oncol. 2011 Jun 01; 29(16):2223-9. PMID: 21483000.
      View in: PubMed
    156. Walker BA, Morgan GJ. Could DNA methylation become a useful measure for multiple myeloma prognoses? Expert Rev Hematol. 2011 Apr; 4(2):125-7. PMID: 21495920.
      View in: PubMed
    157. Anoop P, Riley U, Ethell ME, Treleaven J, Johnson EM, Morgan GJ, Potter MN. First report of fatal human infections with the cactophilic yeast Sporopachydermia cereana. J Infect. 2011 Apr; 62(4):311-3. PMID: 21376753.
      View in: PubMed
    158. Ali MM, Bagratuni T, Davenport EL, Nowak PR, Silva-Santisteban MC, Hardcastle A, McAndrews C, Rowlands MG, Morgan GJ, Aherne W, Collins I, Davies FE, Pearl LH. Structure of the Ire1 autophosphorylation complex and implications for the unfolded protein response. EMBO J. 2011 Mar 02; 30(5):894-905. PMID: 21317875; PMCID: PMC3049214.
    159. Morgan GJ. Can bisphosphonates improve outcomes in patients with newly diagnosed multiple myeloma? Crit Rev Oncol Hematol. 2011 Feb; 77 Suppl 1:S24-30. PMID: 21353177.
      View in: PubMed
    160. Mohammed K, Dignan F, Ethell ME, Davies FE, Morgan GJ, Riley U, Evans S, Potter MN, Shaw BE. An early computed tomography-guided antifungal treatment strategy is safe and efficacious in patients undergoing chemotherapy for high-risk acute leukemia. Leuk Lymphoma. 2011 Feb; 52(2):339-40. PMID: 21281242.
      View in: PubMed
    161. Johnson DC, Corthals SL, Walker BA, Ross FM, Gregory WM, Dickens NJ, Lokhorst HM, Goldschmidt H, Davies FE, Durie BG, Van Ness B, Child JA, Sonneveld P, Morgan GJ. Genetic factors underlying the risk of thalidomide-related neuropathy in patients with multiple myeloma. J Clin Oncol. 2011 Mar 01; 29(7):797-804. PMID: 21245421.
      View in: PubMed
    162. Boyd KD, Davies FE, Morgan GJ. Novel drugs in myeloma: harnessing tumour biology to treat myeloma. Recent Results Cancer Res. 2011; 183:151-87. PMID: 21509685.
      View in: PubMed
    163. Tapper W, Chiecchio L, Dagrada GP, Konn ZJ, Stockley DM, Szubert AJ, Gregory WM, Bell SE, Jackson GH, Child JA, Morgan GJ, Ross FM. Heterogeneity in the prognostic significance of 12p deletion and chromosome 5 amplification in multiple myeloma. J Clin Oncol. 2011 Jan 10; 29(2):e37-9; author reply e40-1. PMID: 21135272.
      View in: PubMed
    164. Morgan GJ, Davies FE, Gregory WM, Cocks K, Bell SE, Szubert AJ, Navarro-Coy N, Drayson MT, Owen RG, Feyler S, Ashcroft AJ, Ross F, Byrne J, Roddie H, Rudin C, Cook G, Jackson GH, Child JA. First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial. Lancet. 2010 Dec 11; 376(9757):1989-99. PMID: 21131037; PMCID: PMC3639680.
    165. Morgan G. Future drug developments in multiple myeloma: an overview of novel lenalidomide-based combination therapies. Blood Rev. 2010 Nov; 24 Suppl 1:S27-32. PMID: 21126634.
      View in: PubMed
    166. Morris C, Drake M, Apperley J, Iacobelli S, van Biezen A, Bjorkstrand B, Goldschmidt H, Harousseau JL, Morgan G, de Witte T, Niederwieser D, Gahrton G. Efficacy and outcome of autologous transplantation in rare myelomas. Haematologica. 2010 Dec; 95(12):2126-33. PMID: 20971818; PMCID: PMC2995572.
    167. Walker BA, Wardell CP, Chiecchio L, Smith EM, Boyd KD, Neri A, Davies FE, Ross FM, Morgan GJ. Aberrant global methylation patterns affect the molecular pathogenesis and prognosis of multiple myeloma. Blood. 2011 Jan 13; 117(2):553-62. PMID: 20944071.
      View in: PubMed
    168. Morgan G, Lipton A. Antitumor effects and anticancer applications of bisphosphonates. Semin Oncol. 2010 Oct; 37 Suppl 2:S30-40. PMID: 21111246.
      View in: PubMed
    169. Boyd KD, Walker BA, Wardell CP, Ross FM, Gregory WM, Davies FE, Morgan GJ. High expression levels of the mammalian target of rapamycin inhibitor DEPTOR are predictive of response to thalidomide in myeloma. Leuk Lymphoma. 2010 Nov; 51(11):2126-9. PMID: 20858096.
      View in: PubMed
    170. van de Donk NW, Lokhorst HM, Dimopoulos M, Cavo M, Morgan G, Einsele H, Kropff M, Schey S, Avet-Loiseau H, Ludwig H, Goldschmidt H, Sonneveld P, Johnsen HE, Bladé J, San-Miguel JF, Palumbo A. Treatment of relapsed and refractory multiple myeloma in the era of novel agents. Cancer Treat Rev. 2011 Jun; 37(4):266-83. PMID: 20863623.
      View in: PubMed
    171. Engelhardt M, Udi J, Kleber M, Spencer A, Rocci A, Knop S, Bruno B, Bringhen S, Pérez-Simón JA, Zweegman S, Driessen C, Patriarca F, Gramatzki M, Terpos E, Sezer O, Kropff M, Straka C, Johnsen HE, Waage A, Boegsted M, Lokhorst H, Hájek R, Morgan G, Boccadoro M, Ludwig H, Cavo M, Polliack A, Sonneveld P, Einsele H, Palumbo A. European Myeloma Network: the 3rd Trialist Forum Consensus Statement from the European experts meeting on multiple myeloma. Leuk Lymphoma. 2010 Nov; 51(11):2006-11. PMID: 20807087.
      View in: PubMed
    172. Löwenberg B, Morgan G, Ossenkoppele GJ, Burnett AK, Zachée P, Dührsen U, Dierickx D, Müller-Tidow C, Sonneveld P, Krug U, Bone E, Flores N, Richardson AF, Hooftman L, Jenkins C, Zweegman S, Davies F. Phase I/II clinical study of Tosedostat, an inhibitor of aminopeptidases, in patients with acute myeloid leukemia and myelodysplasia. J Clin Oncol. 2010 Oct 01; 28(28):4333-8. PMID: 20733120.
      View in: PubMed
    173. Walker BA, Leone PE, Chiecchio L, Dickens NJ, Jenner MW, Boyd KD, Johnson DC, Gonzalez D, Dagrada GP, Protheroe RK, Konn ZJ, Stockley DM, Gregory WM, Davies FE, Ross FM, Morgan GJ. A compendium of myeloma-associated chromosomal copy number abnormalities and their prognostic value. Blood. 2010 Oct 14; 116(15):e56-65. PMID: 20616218.
      View in: PubMed
    174. Schey SA, Morgan GJ, Ramasamy K, Hazel B, Ladon D, Corderoy S, Jenner M, Phekoo K, Boyd K, Davies FE. The addition of cyclophosphamide to lenalidomide and dexamethasone in multiply relapsed/refractory myeloma patients; a phase I/II study. Br J Haematol. 2010 Aug; 150(3):326-33. PMID: 20553268.
      View in: PubMed
    175. Bagratuni T, Wu P, Gonzalez de Castro D, Davenport EL, Dickens NJ, Walker BA, Boyd K, Johnson DC, Gregory W, Morgan GJ, Davies FE. XBP1s levels are implicated in the biology and outcome of myeloma mediating different clinical outcomes to thalidomide-based treatments. Blood. 2010 Jul 15; 116(2):250-3. PMID: 20421453.
      View in: PubMed
    176. Ross FM, Chiecchio L, Dagrada G, Protheroe RK, Stockley DM, Harrison CJ, Cross NC, Szubert AJ, Drayson MT, Morgan GJ. The t(14;20) is a poor prognostic factor in myeloma but is associated with long-term stable disease in monoclonal gammopathies of undetermined significance. Haematologica. 2010 Jul; 95(7):1221-5. PMID: 20410185; PMCID: PMC2895050.
    177. Pratt G, Fenton JA, Allsup D, Fegan C, Morgan GJ, Jackson G, Sunter NJ, Hall AG, Irving JA, Allan JM. A polymorphism in the 3' UTR of IRF4 linked to susceptibility and pathogenesis in chronic lymphocytic leukaemia and Hodgkin lymphoma has limited impact in multiple myeloma. Br J Haematol. 2010 Aug; 150(3):371-3. PMID: 20408839.
      View in: PubMed
    178. Dickens NJ, Walker BA, Leone PE, Johnson DC, Brito JL, Zeisig A, Jenner MW, Boyd KD, Gonzalez D, Gregory WM, Ross FM, Davies FE, Morgan GJ. Homozygous deletion mapping in myeloma samples identifies genes and an expression signature relevant to pathogenesis and outcome. Clin Cancer Res. 2010 Mar 15; 16(6):1856-64. PMID: 20215539; PMCID: PMC2841345.
    179. Roddam PL, Allan JM, Dring AM, Worrillow LJ, Davies FE, Morgan GJ. Non-homologous end-joining gene profiling reveals distinct expression patterns associated with lymphoma and multiple myeloma. Br J Haematol. 2010 Apr; 149(2):258-62. PMID: 20148879.
      View in: PubMed
    180. Ludwig H, Beksac M, Bladé J, Boccadoro M, Cavenagh J, Cavo M, Dimopoulos M, Drach J, Einsele H, Facon T, Goldschmidt H, Harousseau JL, Hess U, Ketterer N, Kropff M, Mendeleeva L, Morgan G, Palumbo A, Plesner T, San Miguel J, Shpilberg O, Sondergeld P, Sonneveld P, Zweegman S. Current multiple myeloma treatment strategies with novel agents: a European perspective. Oncologist. 2010; 15(1):6-25. PMID: 20086168; PMCID: PMC3227886.
    181. Hockley SL, Giannouli S, Morilla A, Wotherspoon A, Morgan GJ, Matutes E, Gonzalez D. Insight into the molecular pathogenesis of hairy cell leukaemia, hairy cell leukaemia variant and splenic marginal zone lymphoma, provided by the analysis of their IGH rearrangements and somatic hypermutation patterns. Br J Haematol. 2010 Feb; 148(4):666-9. PMID: 19863540.
      View in: PubMed
    182. Forsey J, Kenny D, Morgan G, Hayes A, Turner M, Tometzki A, Martin R. Early clinical experience with the new Amplatzer Ductal Occluder II for closure of the persistent arterial duct. Catheter Cardiovasc Interv. 2009 Oct 01; 74(4):615-23. PMID: 19360878.
      View in: PubMed
    183. Chakrabarti S, Kenny D, Morgan G, Curtis SL, Hamilton MC, Wilde P, Tometzki AJ, Turner MS, Martin RP. Balloon expandable stent implantation for native and recurrent coarctation of the aorta--prospective computed tomography assessment of stent integrity, aneurysm formation and stenosis relief. Heart. 2010 Aug; 96(15):1212-6. PMID: 19744966.
      View in: PubMed
    184. Moore HE, Davenport EL, Smith EM, Muralikrishnan S, Dunlop AS, Walker BA, Krige D, Drummond AH, Hooftman L, Morgan GJ, Davies FE. Aminopeptidase inhibition as a targeted treatment strategy in myeloma. Mol Cancer Ther. 2009 Apr; 8(4):762-70. PMID: 19372548.
      View in: PubMed
    185. Kenny D, Morgan G, Bajwa A, Farrow C, Parry A, Caputo M, Tometzki A, Martin R. Evolution of transcatheter closure of perimembranous ventricular septal defects in a single centre. Catheter Cardiovasc Interv. 2009 Mar 01; 73(4):568-75. PMID: 19235245.
      View in: PubMed
    186. Wu P, Davies FE, Boyd K, Thomas K, Dines S, Saso RM, Potter MN, Ethell ME, Shaw BE, Morgan GJ. The impact of extramedullary disease at presentation on the outcome of myeloma. Leuk Lymphoma. 2009 Feb; 50(2):230-5. PMID: 19197724.
      View in: PubMed
    187. Brito JL, Walker B, Jenner M, Dickens NJ, Brown NJ, Ross FM, Avramidou A, Irving JA, Gonzalez D, Davies FE, Morgan GJ. MMSET deregulation affects cell cycle progression and adhesion regulons in t(4;14) myeloma plasma cells. Haematologica. 2009 Jan; 94(1):78-86. PMID: 19059936; PMCID: PMC2625417.
    188. Sirohi B, Powles R, Singhal S, Smith K, Jones RL, Saso R, Kulkarni S, Treleaven J, Swansbury GJ, Potter M, Morgan G, Mehta J. Outcome of high-dose cytarabine-based induction therapy followed by hematopoietic stem cell transplantation in acute myeloid leukemia: influence of karyotype. Leuk Lymphoma. 2008 Dec; 49(12):2284-90. PMID: 19052975.
      View in: PubMed
    189. Cavo M, Attal M, Gertz MA, Giralt S, Ludwig H, Morgan GJ, Anderson KC. The current landscape of multiple myeloma treatment. Leuk Res. 2008 Dec; 32 Suppl 1:S1-24. PMID: 18954677.
      View in: PubMed
    190. Morilla A, Gonzalez de Castro D, Del Giudice I, Osuji N, Else M, Morilla R, Brito Babapulle V, Rudenko H, Matutes E, Dearden C, Catovsky D, Morgan GJ. Combinations of ZAP-70, CD38 and IGHV mutational status as predictors of time to first treatment in CLL. Leuk Lymphoma. 2008 Nov; 49(11):2108-15. PMID: 19021053.
      View in: PubMed
    191. Rudenko HC, Else M, Dearden C, Brito-Babapulle V, Jones C, Dexter T, Fenwick K, Mackay A, Ashworth A, Matutes E, Gonzalez D, Catovsky D, Morgan GJ. Characterising the TP53-deleted subgroup of chronic lymphocytic leukemia: an analysis of additional cytogenetic abnormalities detected by interphase fluorescence in situ hybridisation and array-based comparative genomic hybridisation. Leuk Lymphoma. 2008 Oct; 49(10):1879-86. PMID: 18949611.
      View in: PubMed
    192. Leone PE, Walker BA, Jenner MW, Chiecchio L, Dagrada G, Protheroe RK, Johnson DC, Dickens NJ, Brito JL, Else M, Gonzalez D, Ross FM, Chen-Kiang S, Davies FE, Morgan GJ. Deletions of CDKN2C in multiple myeloma: biological and clinical implications. Clin Cancer Res. 2008 Oct 01; 14(19):6033-41. PMID: 18829482; PMCID: PMC2581792.
    193. Johnson DC, Corthals S, Ramos C, Hoering A, Cocks K, Dickens NJ, Haessler J, Goldschmidt H, Child JA, Bell SE, Jackson G, Baris D, Rajkumar SV, Davies FE, Durie BG, Crowley J, Sonneveld P, Van Ness B, Morgan GJ. Genetic associations with thalidomide mediated venous thrombotic events in myeloma identified using targeted genotyping. Blood. 2008 Dec 15; 112(13):4924-34. PMID: 18805967; PMCID: PMC3601865.
    194. Van Ness B, Ramos C, Haznadar M, Hoering A, Haessler J, Crowley J, Jacobus S, Oken M, Rajkumar V, Greipp P, Barlogie B, Durie B, Katz M, Atluri G, Fang G, Gupta R, Steinbach M, Kumar V, Mushlin R, Johnson D, Morgan G. Genomic variation in myeloma: design, content, and initial application of the Bank On A Cure SNP Panel to detect associations with progression-free survival. BMC Med. 2008 Sep 08; 6:26. PMID: 18778477; PMCID: PMC2553089.
    195. Atkinson SH, Rockett KA, Morgan G, Bejon PA, Sirugo G, O'Connell MA, Hanchard N, Kwiatkowski DP, Prentice AM. Tumor necrosis factor SNP haplotypes are associated with iron deficiency anemia in West African children. Blood. 2008 Nov 15; 112(10):4276-83. PMID: 18716131; PMCID: PMC2581977.
    196. Srikanth M, Davies FE, Wu P, Jenner MW, Ethell ME, Potter MN, Shaw BE, Saso RM, Dines S, Morgan GJ. Survival and outcome of blastoid variant myeloma following treatment with the novel thalidomide containing regime DT-PACE. Eur J Haematol. 2008 Dec; 81(6):432-6. PMID: 18691254.
      View in: PubMed
    197. Cohen S, Morgan G. Monsanto Technology LLC v. Cargill: a matter of construction. Nat Biotechnol. 2008 Mar; 26(3):289-91. PMID: 18327235.
      View in: PubMed
    198. Brito JL, Davies FE, Gonzalez D, Morgan GJ. Streptolysin-O reversible permeabilisation is an effective method to transfect siRNAs into myeloma cells. J Immunol Methods. 2008 Apr 20; 333(1-2):147-55. PMID: 18299137.
      View in: PubMed
    199. Palumbo A, Miguel JS, Sonneveld P, Moreau P, Drach J, Morgan G, Einsele H. Lenalidomide: a new therapy for multiple myeloma. Cancer Treat Rev. 2008 May; 34(3):283-91. PMID: 18230411.
      View in: PubMed
    200. Davenport EL, Morgan GJ, Davies FE. Untangling the unfolded protein response. Cell Cycle. 2008 Apr 01; 7(7):865-9. PMID: 18414035.
      View in: PubMed
    201. Srikanth M, Davies FE, Morgan GJ. An update on drug combinations for treatment of myeloma. Expert Opin Investig Drugs. 2008 Jan; 17(1):1-12. PMID: 18095914.
      View in: PubMed
    202. Gahrton G, Iacobelli S, Bandini G, Björkstrand B, Corradini P, Crawley C, Hegenbart U, Morgan G, Kröger N, Schattenberg A, Schönland SO, Verdonck LF, Volin L, de Witte T, Niederwieser D. Peripheral blood or bone marrow cells in reduced-intensity or myeloablative conditioning allogeneic HLA identical sibling donor transplantation for multiple myeloma. Haematologica. 2007 Nov; 92(11):1513-8. PMID: 18024400.
      View in: PubMed
    203. El-Sherbiny YM, Meade JL, Holmes TD, McGonagle D, Mackie SL, Morgan AW, Cook G, Feyler S, Richards SJ, Davies FE, Morgan GJ, Cook GP. The requirement for DNAM-1, NKG2D, and NKp46 in the natural killer cell-mediated killing of myeloma cells. Cancer Res. 2007 Sep 15; 67(18):8444-9. PMID: 17875681.
      View in: PubMed
    204. Davies FE, Wu P, Jenner M, Srikanth M, Saso R, Morgan GJ. The combination of cyclophosphamide, velcade and dexamethasone induces high response rates with comparable toxicity to velcade alone and velcade plus dexamethasone. Haematologica. 2007 Aug; 92(8):1149-50. PMID: 17650451.
      View in: PubMed
    205. González D, van der Burg M, García-Sanz R, Fenton JA, Langerak AW, González M, van Dongen JJ, San Miguel JF, Morgan GJ. Immunoglobulin gene rearrangements and the pathogenesis of multiple myeloma. Blood. 2007 Nov 01; 110(9):3112-21. PMID: 17634408.
      View in: PubMed
    206. Jenner MW, Leone PE, Walker BA, Ross FM, Johnson DC, Gonzalez D, Chiecchio L, Dachs Cabanas E, Dagrada GP, Nightingale M, Protheroe RK, Stockley D, Else M, Dickens NJ, Cross NC, Davies FE, Morgan GJ. Gene mapping and expression analysis of 16q loss of heterozygosity identifies WWOX and CYLD as being important in determining clinical outcome in multiple myeloma. Blood. 2007 Nov 01; 110(9):3291-300. PMID: 17609426.
      View in: PubMed
    207. Kanagasabaphy P, Morgan GJ, Davies FE. Proteasome inhibition and multiple myeloma. Curr Opin Investig Drugs. 2007 Jun; 8(6):447-51. PMID: 17621873.
      View in: PubMed
    208. Davenport EL, Moore HE, Dunlop AS, Sharp SY, Workman P, Morgan GJ, Davies FE. Heat shock protein inhibition is associated with activation of the unfolded protein response pathway in myeloma plasma cells. Blood. 2007 Oct 01; 110(7):2641-9. PMID: 17525289.
      View in: PubMed
    209. Morgan GJ, Schey SA, Wu P, Srikanth M, Phekoo KJ, Jenner M, Davies FE. Lenalidomide (Revlimid), in combination with cyclophosphamide and dexamethasone (RCD), is an effective and tolerated regimen for myeloma patients. Br J Haematol. 2007 May; 137(3):268-9. PMID: 17408469.
      View in: PubMed
    210. Sirohi B, Powles R, Cavanagh J, Oakervee H, Dyer P, Rintala T, Kulkarni S, Rudin C, Horton C, Treleaven J, Morgan G. Collection of peripheral blood stem cells in new patients with myeloma receiving minimal or no prior cytoreductive therapy. Hematology. 2007 Apr; 12(2):113-5. PMID: 17454191.
      View in: PubMed
    211. Ghattas H, Wallace DL, Solon JA, Henson SM, Zhang Y, Ngom PT, Aspinall R, Morgan G, Griffin GE, Prentice AM, Macallan DC. Long-term effects of perinatal nutrition on T lymphocyte kinetics in young Gambian men. Am J Clin Nutr. 2007 Feb; 85(2):480-7. PMID: 17284747.
      View in: PubMed
    212. Sharma RA, Wotherspoon AC, Cook G, Morgan GJ, Huddart RA. Neuron-specific enolase expression in multiple myeloma. Lancet Oncol. 2006 Nov; 7(11):960. PMID: 17081924.
      View in: PubMed
    213. Walker BA, Morgan GJ. Use of single nucleotide polymorphism-based mapping arrays to detect copy number changes and loss of heterozygosity in multiple myeloma. Clin Lymphoma Myeloma. 2006 Nov; 7(3):186-91. PMID: 17229333.
      View in: PubMed
    214. Wu P, Davies FE, Horton C, Jenner MW, Krishnan B, Alvares CL, Saso R, McCormack R, Dines S, Treleaven JG, Potter MN, Ethell ME, Morgan GJ. The combination of cyclophosphomide, thalidomide and dexamethasone is an effective alternative to cyclophosphamide - vincristine - doxorubicin - methylprednisolone as induction chemotherapy prior to autologous transplantation for multiple myeloma: a case-matched analysis. Leuk Lymphoma. 2006 Nov; 47(11):2335-8. PMID: 17107906.
      View in: PubMed
    215. Rawstron AC, Laycock-Brown G, Hale G, Davies FE, Morgan GJ, Child JA, Hillmen P, Owen RG. CD52 expression patterns in myeloma and the applicability of alemtuzumab therapy. Haematologica. 2006 Nov; 91(11):1577-8. PMID: 17043027.
      View in: PubMed
    216. Lightfoot TJ, Skibola CF, Smith AG, Forrest MS, Adamson PJ, Morgan GJ, Bracci PM, Roman E, Smith MT, Holly EA. Polymorphisms in the oxidative stress genes, superoxide dismutase, glutathione peroxidase and catalase and risk of non-Hodgkin's lymphoma. Haematologica. 2006 Sep; 91(9):1222-7. PMID: 16956821.
      View in: PubMed
    217. Field-Smith A, Morgan GJ, Davies FE. Bortezomib (Velcadetrade mark) in the Treatment of Multiple Myeloma. Ther Clin Risk Manag. 2006 Sep; 2(3):271-9. PMID: 18360602; PMCID: PMC1936263.
    218. Walker BA, Leone PE, Jenner MW, Li C, Gonzalez D, Johnson DC, Ross FM, Davies FE, Morgan GJ. Integration of global SNP-based mapping and expression arrays reveals key regions, mechanisms, and genes important in the pathogenesis of multiple myeloma. Blood. 2006 Sep 01; 108(5):1733-43. PMID: 16705090.
      View in: PubMed
    219. Spink CF, Keen LJ, Mensah FK, Law GR, Bidwell JL, Morgan GJ. Association between non-Hodgkin lymphoma and haplotypes in the TNF region. Br J Haematol. 2006 May; 133(3):293-300. PMID: 16643431.
      View in: PubMed
    220. Morgan GJ, Krishnan B, Jenner M, Davies FE. Advances in oral therapy for multiple myeloma. Lancet Oncol. 2006 Apr; 7(4):316-25. PMID: 16574547.
      View in: PubMed
    221. Spink CF, Gray LC, Davies FE, Morgan GJ, Bidwell JL. Haplotypic structure across the I kappa B alpha gene (NFKBIA) and association with multiple myeloma. Cancer Lett. 2007 Feb 08; 246(1-2):92-9. PMID: 16540234.
      View in: PubMed
    222. Alvares CL, Davies FE, Horton C, Patel G, Powles R, Morgan GJ. The role of second autografts in the management of myeloma at first relapse. Haematologica. 2006 Jan; 91(1):141-2. PMID: 16434386.
      View in: PubMed
    223. Rothman N, Skibola CF, Wang SS, Morgan G, Lan Q, Smith MT, Spinelli JJ, Willett E, De Sanjose S, Cocco P, Berndt SI, Brennan P, Brooks-Wilson A, Wacholder S, Becker N, Hartge P, Zheng T, Roman E, Holly EA, Boffetta P, Armstrong B, Cozen W, Linet M, Bosch FX, Ennas MG, Holford TR, Gallagher RP, Rollinson S, Bracci PM, Cerhan JR, Whitby D, Moore PS, Leaderer B, Lai A, Spink C, Davis S, Bosch R, Scarpa A, Zhang Y, Severson RK, Yeager M, Chanock S, Nieters A. Genetic variation in TNF and IL10 and risk of non-Hodgkin lymphoma: a report from the InterLymph Consortium. Lancet Oncol. 2006 Jan; 7(1):27-38. PMID: 16389181.
      View in: PubMed
    224. Augustson BM, Begum G, Dunn JA, Barth NJ, Davies F, Morgan G, Behrens J, Smith A, Child JA, Drayson MT. Early mortality after diagnosis of multiple myeloma: analysis of patients entered onto the United kingdom Medical Research Council trials between 1980 and 2002--Medical Research Council Adult Leukaemia Working Party. J Clin Oncol. 2005 Dec 20; 23(36):9219-26. PMID: 16275935.
      View in: PubMed
    225. Mitsiades CS, Mitsiades NS, McMullan CJ, Poulaki V, Kung AL, Davies FE, Morgan G, Akiyama M, Shringarpure R, Munshi NC, Richardson PG, Hideshima T, Chauhan D, Gu X, Bailey C, Joseph M, Libermann TA, Rosen NS, Anderson KC. Antimyeloma activity of heat shock protein-90 inhibition. Blood. 2006 Feb 01; 107(3):1092-100. PMID: 16234364; PMCID: PMC1895907.
    226. Al Rayes MH, Rawstron AC, Morgan GJ, Davies FE. The bone marrow microenvironment influences the differential chemokine receptor expression of normal and neoplastic plasma cells. Blood. 2005 Jun 15; 105(12):4895-6. PMID: 15933065.
      View in: PubMed
    227. Skibola CF, Lightfoot T, Agana L, Smith A, Rollinson S, Kao A, Adamson P, Morgan GJ, Smith MT, Roman E. Polymorphisms in cytochrome P450 17A1 and risk of non-Hodgkin lymphoma. Br J Haematol. 2005 Jun; 129(5):618-21. PMID: 15916684.
      View in: PubMed
    228. Alvares CL, Davies FE, Horton C, Patel G, Powles R, Sirohi B, Zuha R, Gatt A, Saso R, Treleaven JG, Dearden CE, Potter MN, Ethell ME, Morgan GJ. Long-term outcomes of previously untreated myeloma patients: responses to induction chemotherapy and high-dose melphalan incorporated within a risk stratification model can help to direct the use of novel treatments. Br J Haematol. 2005 Jun; 129(5):607-14. PMID: 15916682.
      View in: PubMed
    229. Morgan GJ, Adamson PJ, Mensah FK, Spink CF, Law GR, Keen LJ, Roman E, Davies FE, Rollinson S, Child JA, Bidwell JL. Haplotypes in the tumour necrosis factor region and myeloma. Br J Haematol. 2005 May; 129(3):358-65. PMID: 15842659.
      View in: PubMed
    230. Greipp PR, San Miguel J, Durie BG, Crowley JJ, Barlogie B, Bladé J, Boccadoro M, Child JA, Avet-Loiseau H, Harousseau JL, Kyle RA, Lahuerta JJ, Ludwig H, Morgan G, Powles R, Shimizu K, Shustik C, Sonneveld P, Tosi P, Turesson I, Westin J. International staging system for multiple myeloma. J Clin Oncol. 2005 May 20; 23(15):3412-20. PMID: 15809451.
      View in: PubMed
    231. Hill A, Short MA, Varghese C, Kusumakumary P, Kumari P, Morgan GJ. The t(12:21) is underrepresented in childhood B-lineage acute lymphoblastic leukemia in Kerala, Southern India. Haematologica. 2005 Mar; 90(3):414-6. PMID: 15749681.
      View in: PubMed
    232. Dring AM, Davies FE, Fenton JA, Roddam PL, Scott K, Gonzalez D, Rollinson S, Rawstron AC, Rees-Unwin KS, Li C, Munshi NC, Anderson KC, Morgan GJ. A global expression-based analysis of the consequences of the t(4;14) translocation in myeloma. Clin Cancer Res. 2004 Sep 01; 10(17):5692-701. PMID: 15355895.
      View in: PubMed
    233. Allan JM, Smith AG, Wheatley K, Hills RK, Travis LB, Hill DA, Swirsky DM, Morgan GJ, Wild CP. Genetic variation in XPD predicts treatment outcome and risk of acute myeloid leukemia following chemotherapy. Blood. 2004 Dec 15; 104(13):3872-7. PMID: 15339847.
      View in: PubMed
    234. Velangi MR, Matheson EC, Morgan GJ, Jackson GH, Taylor PR, Hall AG, Irving JA. DNA mismatch repair pathway defects in the pathogenesis and evolution of myeloma. Carcinogenesis. 2004 Oct; 25(10):1795-803. PMID: 15142887.
      View in: PubMed
    235. Milligan DW, Fernandes S, Dasgupta R, Davies FE, Matutes E, Fegan CD, McConkey C, Child JA, Cunningham D, Morgan GJ, Catovsky D. Results of the MRC pilot study show autografting for younger patients with chronic lymphocytic leukemia is safe and achieves a high percentage of molecular responses. Blood. 2005 Jan 01; 105(1):397-404. PMID: 15117764.
      View in: PubMed
    236. Fenton JA, Pratt G, Rothwell DG, Rawstron AC, Morgan GJ. Translocation t(11;14) in multiple myeloma: Analysis of translocation breakpoints on der(11) and der(14) chromosomes suggests complex molecular mechanisms of recombination. Genes Chromosomes Cancer. 2004 Feb; 39(2):151-5. PMID: 14695995.
      View in: PubMed
    237. Neven B, Callebaut I, Prieur AM, Feldmann J, Bodemer C, Lepore L, Derfalvi B, Benjaponpitak S, Vesely R, Sauvain MJ, Oertle S, Allen R, Morgan G, Borkhardt A, Hill C, Gardner-Medwin J, Fischer A, de Saint Basile G. Molecular basis of the spectral expression of CIAS1 mutations associated with phagocytic cell-mediated autoinflammatory disorders CINCA/NOMID, MWS, and FCU. Blood. 2004 Apr 01; 103(7):2809-15. PMID: 14630794.
      View in: PubMed
    238. Davies FE, Dring AM, Li C, Rawstron AC, Shammas MA, O'Connor SM, Fenton JA, Hideshima T, Chauhan D, Tai IT, Robinson E, Auclair D, Rees K, Gonzalez D, Ashcroft AJ, Dasgupta R, Mitsiades C, Mitsiades N, Chen LB, Wong WH, Munshi NC, Morgan GJ, Anderson KC. Insights into the multistep transformation of MGUS to myeloma using microarray expression analysis. Blood. 2003 Dec 15; 102(13):4504-11. PMID: 12947006.
      View in: PubMed
    239. Worrillow LJ, Travis LB, Smith AG, Rollinson S, Smith AJ, Wild CP, Holowaty EJ, Kohler BA, Wiklund T, Pukkala E, Roman E, Morgan GJ, Allan JM. An intron splice acceptor polymorphism in hMSH2 and risk of leukemia after treatment with chemotherapeutic alkylating agents. Clin Cancer Res. 2003 Aug 01; 9(8):3012-20. PMID: 12912950.
      View in: PubMed
    240. Dasgupta RK, Adamson PJ, Davies FE, Rollinson S, Roddam PL, Ashcroft AJ, Dring AM, Fenton JA, Child JA, Allan JM, Morgan GJ. Polymorphic variation in GSTP1 modulates outcome following therapy for multiple myeloma. Blood. 2003 Oct 01; 102(7):2345-50. PMID: 12791655.
      View in: PubMed
    241. Barrans SL, Evans PA, O'Connor SJ, Kendall SJ, Owen RG, Haynes AP, Morgan GJ, Jack AS. The t(14;18) is associated with germinal center-derived diffuse large B-cell lymphoma and is a strong predictor of outcome. Clin Cancer Res. 2003 Jun; 9(6):2133-9. PMID: 12796378.
      View in: PubMed
    242. Child JA, Morgan GJ, Davies FE, Owen RG, Bell SE, Hawkins K, Brown J, Drayson MT, Selby PJ. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med. 2003 May 08; 348(19):1875-83. PMID: 12736280.
      View in: PubMed
    243. Ashcroft AJ, Davies FE, Morgan GJ. Aetiology of bone disease and the role of bisphosphonates in multiple myeloma. Lancet Oncol. 2003 May; 4(5):284-92. PMID: 12732166.
      View in: PubMed
    244. Rollinson S, Levene AP, Mensah FK, Roddam PL, Allan JM, Diss TC, Roman E, Jack A, MacLennan K, Dixon MF, Morgan GJ. Gastric marginal zone lymphoma is associated with polymorphisms in genes involved in inflammatory response and antioxidative capacity. Blood. 2003 Aug 01; 102(3):1007-11. PMID: 12676777.
      View in: PubMed
    245. Roddam PL, Allan JM, Rollinson S, Smith AG, Willett EV, Swirsky D, Roman E, Morgan GJ. Poor metabolizer status at the cytochrome P450 2C9 and 2D6 loci does not modulate susceptibility to therapy-related acute myeloid leukaemia. Br J Haematol. 2003 Apr; 121(1):192-4. PMID: 12670355.
      View in: PubMed
    246. Fenton JA, Pratt G, Rawstron AC, Sibley K, Rothwell D, Yates Z, Dring A, Richards SJ, Ashcroft AJ, Davies FE, Owen RG, Child JA, Morgan GJ. Genomic characterization of the chromosomal breakpoints of t(4;14) of multiple myeloma suggests more than one possible aetiological mechanism. Oncogene. 2003 Feb 20; 22(7):1103-13. PMID: 12592397.
      View in: PubMed
    247. Durie BG, Kyle RA, Belch A, Bensinger W, Blade J, Boccadoro M, Child JA, Comenzo R, Djulbegovic B, Fantl D, Gahrton G, Harousseau JL, Hungria V, Joshua D, Ludwig H, Mehta J, Morales AR, Morgan G, Nouel A, Oken M, Powles R, Roodman D, San Miguel J, Shimizu K, Singhal S, Sirohi B, Sonneveld P, Tricot G, Van Ness B. Myeloma management guidelines: a consensus report from the Scientific Advisors of the International Myeloma Foundation. Hematol J. 2003; 4(6):379-98. PMID: 14671610.
      View in: PubMed
    248. Podar K, Tai YT, Cole CE, Hideshima T, Sattler M, Hamblin A, Mitsiades N, Schlossman RL, Davies FE, Morgan GJ, Munshi NC, Chauhan D, Anderson KC. Essential role of caveolae in interleukin-6- and insulin-like growth factor I-triggered Akt-1-mediated survival of multiple myeloma cells. J Biol Chem. 2003 Feb 21; 278(8):5794-801. PMID: 12482878.
      View in: PubMed
    249. Bowen DT, Frew ME, Rollinson S, Roddam PL, Dring A, Smith MT, Langabeer SE, Morgan GJ. CYP1A1*2B (Val) allele is overrepresented in a subgroup of acute myeloid leukemia patients with poor-risk karyotype associated with NRAS mutation, but not associated with FLT3 internal tandem duplication. Blood. 2003 Apr 01; 101(7):2770-4. PMID: 12468438.
      View in: PubMed
    250. Rawstron AC, Davies FE, DasGupta R, Ashcroft AJ, Patmore R, Drayson MT, Owen RG, Jack AS, Child JA, Morgan GJ. Flow cytometric disease monitoring in multiple myeloma: the relationship between normal and neoplastic plasma cells predicts outcome after transplantation. Blood. 2002 Nov 01; 100(9):3095-100. PMID: 12384404.
      View in: PubMed
    251. Sibley K, Fenton JA, Dring AM, Ashcroft AJ, Rawstron AC, Morgan GJ. A molecular study of the t(4;14) in multiple myeloma. Br J Haematol. 2002 Aug; 118(2):514-20. PMID: 12139740.
      View in: PubMed
    252. Rawstron AC, Green MJ, Kuzmicki A, Kennedy B, Fenton JA, Evans PA, O'Connor SJ, Richards SJ, Morgan GJ, Jack AS, Hillmen P. Monoclonal B lymphocytes with the characteristics of "indolent" chronic lymphocytic leukemia are present in 3.5% of adults with normal blood counts. Blood. 2002 Jul 15; 100(2):635-9. PMID: 12091358.
      View in: PubMed
    253. Gowans D, O'Sullivan A, Rollinson S, Roddam P, Groves M, Fegan C, Morgan G, Bowen D. Allele and haplotype frequency at human leucocyte antigen class I/II and immunomodulatory cytokine loci in patients with myelodysplasia and acute myeloid leukaemia: in search of an autoimmune aetiology. Br J Haematol. 2002 Jun; 117(3):541-5. PMID: 12028020.
      View in: PubMed
    254. Skibola CF, Smith MT, Hubbard A, Shane B, Roberts AC, Law GR, Rollinson S, Roman E, Cartwright RA, Morgan GJ. Polymorphisms in the thymidylate synthase and serine hydroxymethyltransferase genes and risk of adult acute lymphocytic leukemia. Blood. 2002 May 15; 99(10):3786-91. PMID: 11986237.
      View in: PubMed
    255. Barrans SL, O'Connor SJ, Evans PA, Davies FE, Owen RG, Haynes AP, Morgan GJ, Jack AS. Rearrangement of the BCL6 locus at 3q27 is an independent poor prognostic factor in nodal diffuse large B-cell lymphoma. Br J Haematol. 2002 May; 117(2):322-32. PMID: 11972514.
      View in: PubMed
    256. Lebailly P, Willett EV, Moorman AV, Roman E, Cartwright R, Morgan GJ, Wild CP. Genetic polymorphisms in microsomal epoxide hydrolase and susceptibility to adult acute myeloid leukaemia with defined cytogenetic abnormalities. Br J Haematol. 2002 Mar; 116(3):587-94. PMID: 11849215.
      View in: PubMed
    257. Davies FE, Rawstron AC, Owen RG, Morgan GJ. Minimal residual disease monitoring in multiple myeloma. Best Pract Res Clin Haematol. 2002 Mar; 15(1):197-222. PMID: 11987924.
      View in: PubMed
    258. Barrans SL, Carter I, Owen RG, Davies FE, Patmore RD, Haynes AP, Morgan GJ, Jack AS. Germinal center phenotype and bcl-2 expression combined with the International Prognostic Index improves patient risk stratification in diffuse large B-cell lymphoma. Blood. 2002 Feb 15; 99(4):1136-43. PMID: 11830458.
      View in: PubMed
    259. Fenton JA, Vaandrager JW, Aarts WM, Bende RJ, Heering K, van Dijk M, Morgan G, van Noesel CJ, Schuuring E, Kluin PM. Follicular lymphoma with a novel t(14;18) breakpoint involving the immunoglobulin heavy chain switch mu region indicates an origin from germinal center B cells. Blood. 2002 Jan 15; 99(2):716-8. PMID: 11781262.
      View in: PubMed
    Morgan's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    _
    Co-Authors Expand Description
    _
    Similar People Expand Description
    _
    Same Department Expand Description
    Physical Neighbors Expand Description
    _